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Using the 2013 edition of the Truven Marketscan ® Administrative Claims database, this study
looks to link the expected side effects of Beers Criteria medications to logical hospital
admissions. This study sets to examine hospital admissions and emergency department visits for
community-dwelling elderly individuals 65 years or older specifically for falls and fracture as
well as confusion and delirium admissions. These hospital admission types constitute a
significant number of admissions the elderly experience due to the medication side effects which
affect balance, gait, and cognition. Through the use of 2.6 million propensity-score matched
patients, 1.297 million having been exposed to Beers Criteria medications and 1.297 million
patients not exposed, this study was able to confirm the linkage between the expected side effects
of the medication classes and their logical hospital admissions. Antipsychotics and
benzodiazepines were the most frequent prescribed medications to both groups of admission and
were also associated with the highest increase in risk of hospitalizations. Future research into
medication specific research in regards to falls and fractures, and confusion and delirium in the
elderly is warranted.
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1) CHAPTER I INTRODUCTION
In the most recent report by the National Center for Health Statistics published in June
2019, it is estimated that the overall life expectancy of a person in the United States is 78.6 years
for all races and sexes and this value has been on a steady increase since 1970 (Arias & Xu,
2019). There are several issues that a population who is not only aging and staying alive longer
but a population who is also steadily increasing can cause; one of the most important and
currently pressing issues is that of healthcare expenditures associated with aging. Many people
may think the aging population “spend less money” as they are less able to travel, take part in
recreational activities but this is not entirely true.
The question we struggle with is not completely clinical. To begin driving the total
amount of healthcare expenditures in the United States down, we must first understand the
absolute underlying causes of these expenditures and how to prevent them from occurring.
Throughout much of the literature on healthcare expenditures in elderly populations there is a
consistent trend present, what actions, both internal and external to the healthcare system, can we
take to prevent the unplanned hospitalization of elderly patients? This question, while thoroughly
researched, the true underlying question is not how we can prevent these unplanned admissions,
but how can we predict future unplanned hospitalizations based on the medical and statistical
information we currently have on the aging and elderly population.
It is consistently referenced through the literature on unplanned hospitalizations in elderly
populations that the availability of a validated predictive model or integrated clinical decision
support tool which can predict future hospitalizations would be the crucial first step in reducing
the number of preventable readmissions (LaMantia et al., 2010; Parameswaran Nair, Chalmers,
Peterson, et al., 2016). There have been several attempts to build such a model but the attempts
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by Alassaad et al. (2015), Chang et al. (2005), LaMantia et al. (2010), and Parameswaran Nair,
Chalmers, Connolly, et al. (2016) have only been able to build models with a concordance
statistic, or c-statistic, of 0.73 at the greatest. While there is no published statistical rational, the
c-statistic that is accepted in medical studies showing high discriminative power is 0.95 (Caetano
et al., 2018).
One consequence of the growing elderly population in which we will focus on in this
study is the concept of polypharmacy. While there is no standardized definition of
“polypharmacy” across the literature, it is defined as the prescribing of multiple clinically
indicated medications to one individual from one or more prescribers, to which these
medications are unnecessary duplications of treatment, harmful to the patient, or whose effect
could be synergistic or antagonistic when mixed with other medications (Dagli & Sharma, 2014;
Endsley, 2018; Hammond & Wilson, 2013; Quinn & Shah, 2017; Sergi et al., 2011). In the
United States, 61% of adults over the age of 65 have two or more chronic conditions, which
further drives up the prevalence of polypharmacy from overprescribing practices and insufficient
patient monitoring and follow-up (Quinn & Shah, 2017). Polypharmacy, adverse drug events
(ADE), and drug related mortality are a few of the most burdensome affects from aging on the
healthcare ecosystem today, which is why it is so very important to address this problem (Quinn
& Shah, 2017).
A 2018 study by O’Neill Roldan aimed to measure healthcare resource utilization of
elderly patients and the resulting healthcare costs associated with the use of potentially
inappropriate medications. This study found that individuals whom were prescribed any Beers
Criteria medication experienced a greater number of hospital admissions for a longer length of
stay compared to a matched group of individuals not taking these medications (O'Neill Roldan,
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2018). Multiple studies have already determined that a relationship exists between elderly
patients taking medications on the Beers Criteria and unplanned hospitalizations. However, it is
not known if these additional hospital admissions are logically related to the expected side
effects of Beers drug used.
This study will use the O’Neill Roldan (2018) data set to identify the rate of readmissions
that are logically linked to the Beers Criteria drugs. We will examine hospital admissions and
emergency department visits (ED) for two key types of events associated with a broad array of
medication classes listed on Beers Criteria:
1) Admissions for falls and/or fractures in patients taking medications on the Beers
Criteria which are not recommended because of their effect on balance and gait, and
2) Admissions for confusion and/or delirium patients taking medications on the Beers
Criteria which are not recommended because of their effect because on cognition and
a persons’ ability to live independently.
The population for this study will be secondary-use of the data set from an existing research
study performed by O'Neill Roldan (2018) and colleagues at the Medical University of South
Carolina. This dataset contains roughly 2.6 million patients extracted from the 2013 Truven
Marketscan® Administrative Claims Database. The data are de-identified and the study meets
the criteria for non-human research which requires no informed consent. Work on this patient
cohort has been previously published in: “Simpson, K. N., Seamon, B. A., Hand, B. N., Roldan,
C. O., Taber, D. J., Moran, W. P., & Simpson, A. N. (2018). Effect of frailty on resource use and
cost for Medicare patients. J Comp Eff Res, 7(8), 817-825. https://doi.org/10.2217/cer-20180029”.
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2) CHAPTER II LITERATURE REVIEW
As previously discussed, there is extensive literature available in determining if an
association present between Beers Criteria medications and an increased likelihood of a patient
experiencing an unplanned hospitalization. Since that determination, researchers have sought to
expand the domain and attempt to predict these unplanned hospitalizations, however, as of the
time of this writing to our knowledge, there is still no validated tool available that can predict
unplanned hospitalizations based solely on Beers Criteria and existing patient characteristics.
Clinically, elderly patients function and require different treatment and care provided in a
manner different than your average adult. For example, elderly patients may have a decrease in
kidney or liver function, metabolize and excrete medications at a faster or slower rate, an
increased number of comorbid conditions, and an increased potential to experience an adverse
drug event (ADE) (Berryman et al., 2012; Gokce Kutsal et al., 2009; LaMantia et al., 2010).
Older patients are far more susceptible to adverse effects of pharmaceutical medications, yet
studies have shown that high dose and very high doses of these inappropriate medications are
still being used in the care and treatment of elderly patients. A study by Mitchell et al. (2017)
found in two US academic medical centers in a 6-month period that 3,394 doses of potentially
inappropriate medications were administered to 1,364 different patients. Mitchell et al. (2017)
calls attention to the potentially unsafe use and higher than recommended dosing of potentially
inappropriate medications being used in emergency departments.
2.1

American Geriatric Society Beers Criteria
The American Geriatrics Society (AGS), since 2011, has been the organization

responsible for maintaining the Beers Criteria for Potentially Inappropriate Medication Use in
Older Adults. First published in 1991, the Beers Criteria from the AGS is the oldest list of
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medications that outside of extraordinary circumstances, should be avoided in the care and
treatment of elderly individuals (American Geriatrics Society Beers Criteria® Update Expert
Panel, 2019). The AGS publishes a revision to the Beers Criteria every three years by convening
a panel of medical experts to review any newly published evidence and determine if any of the
Beers Criteria recommendations should be removed or changed, or if there are new
recommendations that should be added. There are five primary sections which make up the
complete Beers Criteria list, potentially inappropriate medications for older adults, medications
that should be avoided based on the patient’s condition, medications that should be used with
caution based on the patient’s condition, medications with severe drug-drug interactions, and
medications which require dose adjustment based on the patients renal function (American
Geriatrics Society Beers Criteria® Update Expert Panel, 2019).
In the 2019 revision of the Beers Criteria there were several notable changes made by the
expert panel. Compared to the 2015 revision, the 2019 revision removed a number of
medications the panel removed because “the drug-related problem was not sufficiently unique to
older adults” and “they [the decisions] were made to help keep the AGS Beers Criteria®
streamlined and focused on medications particularly problematic for older adults” (American
Geriatrics Society Beers Criteria® Update Expert Panel, 2019). Overall the expert panel decided
to remove 25 medications or classes of medications from the Beers Criteria and add new
approved medications to the medications to use with caution, the drug-drug interaction, and the
potentially inappropriate medications lists for 2019 (American Geriatrics Society Beers
Criteria® Update Expert Panel, 2019). The AGS summarized their changes from the 2015 to
2019 revision of the Beers Criteria in table 10 of their publication and is presented below in
Figure 1.
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Figure 1: Medications/Criterion Modified Since 2015 American Geriatrics Society Beers
Criteria®

For the purposes of this study, the 2012 edition of the Beers Criteria will be used as that
was the most recent update of the Beers Criteria in tandem with the availability of the Truven
Marketscan® dataset the O’Neill Roldan (2018) study used. The medications that comprise the
2012 Beers Criteria are available in Appendix A while the most recent version of the Beers
Criteria, the 2019 revision, is available in Appendix B.
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2.1.1 The Delphi Analysis Methodology
The AGS Beers Criteria, along with the other inappropriate medication lists discussed in
section 2.2 Non-Beers Criteria Medication Guides, were all developed using the Delphi Method
to reach a shared consensus among a group or panel of experts (McMillan et al., 2016).
Developed in 1953 by the Rand Corporation, the Delphi Method uses multiple series of selfguided questionnaires that solicits individual feedback from the panel members or expert
allowing for the confidentiality of their comments if the situation should require such (McMillan
et al., 2016). The Delphi Method is a useful tool because it is intrinsically industry agnostic,
meaning this methodology can be used and implemented outside of healthcare and health
services research (McMillan et al., 2016; Powell, 2003). The Delphi Method is used when a
specific research initiative needs to solicit, and eventually combine, the opinions and expertise of
a group of subject matter experts (SMEs) when there is a general lack of agreement on a specific
topic (Powell, 2003).
The advantage of using the Delphi Method for building guidelines and frameworks is the
inclusion of a standard 3, 5, 7, or 9-point Likert scale rating for a quantitative evaluation as well
as the ability for the participant to provide a free-text response to elaborate or justify their rating
(McMillan et al., 2016). Once the first Delphi survey round is complete, the responses are
collected and in turn used to develop the survey for the second Delphi round which contains the
participants original rating and the groups median rating for each question, as well as a selection
of the free-text responses to provide thought and insight from the other panel members
(McMillan et al., 2016). The second round of the Delphi Method allows the participant to review
the general rating as compared with their own and provides the opportunity for the participant to
keep their previous rating or adjust it based on the information provided by the other participants
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(McMillan et al., 2016). Because the second round of the Delphi Method is based on the results
of the first round, Powell (2003) mentions this [second] round is when the researcher will either
see, or begin to see, the opinions provided converge and become more uniform. Once the second
round of surveying is complete, the researcher can then combine the participant’s adjusted
ratings and analyze the results.
According to McMillan et al. (2016), agreement on a topic is typically defined when the
median score is greater than 77% of the maximum score for the Likert scale used in the survey.
For example, if the survey used a 9-point Likert scale range, then agreement on a topic would be
considered reached if the median score was greater than or equal to 7 (McMillan et al., 2016).
Additionally, as described by McMillan et al. (2016), disagreement on a topic is considered
when one-third of the number of respondents score the question or statement on the opposite end
of the scale when compared to the other participants. This definition of agreement and
disagreement on a topic is of course dependent upon the topic in which the Delphi Methodology
is being used for. In a systematic review by Powell (2003), she found varying definitions of
panel agreement and disagreement. In one study mentioned by Powell (2003), the outcome of the
Delphi Method required 100% agreement between the participants, another only requiring 51%
consensus, and others listed no specific threshold which was used.
With regards to the Delphi Method, while this methodology is well understood,
researchers using this method have been called upon to explain and explicitly define the criteria
their study is using for consensus among participants (Diamond et al., 2014). Various systematic
reviews have revealed the criteria used to define agreement and overall consensus is both
defined, and reported, poorly in published literature (Diamond et al., 2014; Toronto, 2017).
Researchers using the Delphi Method should be specifically trained in the proper execution of
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this tool due several caveats and complexities of the methodology itself. When used properly, the
Delphi, or newer e-Delphi (electronic Delphi) methodology is an incredibly useful tool for
collecting, aggregating, and eventually unifying the opinions of experts on a specific topic
(Hasson et al., 2000; Toronto, 2017).
2.1.2 In regards to Potentially Inappropriate Medications
Beers Criteria is one of the many examples of potentially inappropriate medications lists
published and in use today that recommend against use in the care and treatment of elderly
individuals. Baldoni et al. (2014) published a study after interviewing 1,000 elderly Brazilian
residents to identify not only the clinical, but the socioeconomic and demographic factors that
may attribute PIM use in those elderly patients. This study also compared PIM usage using both
the 2003 and the 2012 versions of the Beers Criteria and tested the agreement between the two
versions directly. Baldoni et al. (2014) found was that the list of factors associated with PIM
usage in their patients were the same between the 2003 and 2012 versions of Beers Criteria
(female, self-medicates, use of OTCs, psychotropic medications, polypharmacy, and common
ADE symptoms), there was a difference in the percentage of PIMs identified between the two
versions of the criteria. The 2003 revision of Beers Criteria identified 48.0% of PIMs while the
2012 version identified 59.2% (Baldoni et al., 2014). Using the McNemar’s test, Baldoni et al.
(2014) determined that the difference in identification percentages between the two revisions was
indeed significant. Outside of the analysis by Baldoni et al. (2014), the significant change in
identification percentage may also have been due to the 2012 revision. The American Geriatric
Society indicated that the 2012 revision of the Beers Criteria was one of the largest overhauls of
the criteria as this was the first revision where the AGS was responsible for writing and
publishing said update (American Geriatrics Society Beers Criteria Update Expert Panel, 2012).
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There is a significant amount of literature available on Beers Criteria and the prevalence
of potentially inappropriate medications in the elderly population. Research has shown the risk
for unplanned hospitalizations increases as the number of active PIMs the patient is taking also
increases (Gallagher et al., 2008; Price et al., 2014a, 2014b).
2.1.3 In regards to Drug Exposure and Unplanned Hospitalizations
As discussed earlier, one of the leading causes of unplanned hospitalizations in the
elderly population is in fact from adverse drug events (Price et al., 2014b). Studies have shown
that in elderly populations, an increase in polypharmacy has been correlated with an increased
risk of the patient experiencing an adverse drug event, which has also been correlated with an
significant increased risk of unplanned hospitalizations (Sarwar et al., 2018; Wimmer et al.,
2014). Because of these, and other similar findings correlating the use of PIMs to unplanned
hospitalizations, being able to predict future unplanned hospitalizations in this population.
A 2018 Pakistani study by Sarwar et al. found that in a population of 385 geriatric
patients, 61% of participants were taking 5-9 prescription medications, and 56.4% of participants
had an unplanned hospitalization that could be traced back to one of the PIMs they were taking.
Sarwar et al. (2018) also found patients considered to have polypharmacy (5-9 medications) and
excessive polypharmacy (10 or more medications) were 2.5 times and 38 times more likely to
have an unplanned hospitalization, respectively (Sarwar et al., 2018).
2.2

Non-Beers Criteria Medication Guides
While the AGS Beers Criteria is a valuable tool for evaluating the pharmacologic care

and treatment of an elderly patient, there are other generally accepted medication management
criteria available as well. While there are others, two of the most common of these Beers
alternatives of explicit or expert criteria is the Screening Tool to Alert Doctors to Right
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Treatment (START)/Screening Tool for Older Persons’ Prescriptions (STOPP) and the Fit fOR
The Aged (EURO FORTA) listing.
2.2.1 START/STOPP Criteria
The START/STOPP criteria was first published in 2008 from an Irish study compiled
using the Delphi consensus method, similar to Beers Criteria, and most recently updated in 2014
(Corsonello et al., 2012; Curtin et al., 2019). The START criteria consists of 34 prescribing
indications for medications that have been either shown or are likely to provide a benefit to the
patient while the STOPP criteria contains 80 inappropriate prescribing practices when caring for
elderly patients (Corsonello et al., 2012; O'Mahony et al., 2015). While the STOPP criteria and
the Beers Criteria have a similar purpose, there are a number of differences between the two that
exist. First, the STOPP criteria is organized by body system making it easier for clinicians to
navigate, while the Beers Criteria is organized by function as discussed earlier (Corsonello et al.,
2012). Second, because drug approval and availability differ between the United States and most
European countries, the two criteria primarily focus on the pharmaceuticals that are available for
use in their geographic area. Next considering the pharmaceuticals that do overlap on both lists,
there are a number of items that are present on the STOPP criteria that are not present on the
Beers Criteria (Corsonello et al., 2012). This could be for a number of reasons, the specific
evidence taken into consideration, scoring methods when evaluating the literature and evidence,
or differences in validation methods (Corsonello et al., 2012). And lastly, the START/STOPP
criteria have been used in various randomized clinical trials (RCT) and have shown evidence of a
clinical benefit when used as an intervention tool; Beers Criteria has not (Curtin et al., 2019).
There has been a number of studies performed to access the head to head performance of
START/STOPP and the Beers Criteria. A 2014 Spanish study by Hudhra et al. showed within a
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population of 624 patients, Beers Criteria found 22.9% of PIMs while the STOPP criteria found
38.4% of PIMs. Their research also found that the number of PIMs increased with an increase in
Charlson Index Score and the number of drugs prescribed to the specific patient (Hudhra et al.,
2014). In another study by Salgueiro-Vázquez et al. (2016) found in a comparison between Beers
Criteria and STOPP, that within a sample of 223 patients older than 65 years old and taking 10 or
more medications per day, that 63.2% of patients met a Beers Criteria PIM and 73.9% of patients
met a STOPP PIM. Additionally, a 2012 study from India echoes similar results as above; 19.8%
PIP identification by START/STOPP while only 7.3% PIP identification by Beers Criteria
(Karandikar et al., 2013).
An Irish study by Hamilton et al. (2011) found that ADEs in their patient sample were
identified by STOPP criteria 2.54 times more often than with Beers Criteria and 67.7% of the
time STOPP was involved with the identification of an avoidable ADE compared to Beers
Criteria at 28.5%. Hamilton et al. (2011) presents that the use of STOPP criteria is more
clinically relevant because of its ability to identify PIMs that would result in an ADE.
Studies have shown that there is a difference in sensitivity between Beers Criteria and
using START/STOPP. A study by Brown et al. (2014) shows the inverse result from the studies
discussed above. Brown et al. (2014) found that in a retrospective cohort of 174,275 patients,
Beers Criteria was able to identify 34.1% of PIMs while STOPP was only able to identify 27.6%.
Similarly in a 2015 Brazilian study, Oliveira et al. (2015) found that in a sample of 142 randomly
selected patients, Beers Criteria was able to identify 51.8% of PIMs and STOPP was able to
identify 33.8% of PIMs. A 2018 study by Sakr et al. with a group of 350 patient participants
found that Beers Criteria was able to identify 20.4% of PIMs while STOPP was only able to
identify 6.2% of PIMs. This study added an additional element, the Treatment Satisfaction
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Questionnaire for Medications, or TSQM. The TSQM is a 14 item questionnaire aimed to
evaluate the patient perceived success of the treatment provided to them (Sakr et al., 2018). This
study also found that when either the Beers Criteria or STOPP criteria was actively being used in
the experimental arm, the individual TSQM scores for patients with PIMs was significantly
lower than for patients without PIMs (Sakr et al., 2018).
As discussed previously, the START/STOPP criteria was developed in Europe and
contains medications that are not available for use in the United States and these medications do
not appear on the Beers Criteria. When considering the international use of Beers Criteria, this
needs to be taken into consideration as the two are not equally matched.
2.2.2 EURO FORTA
The Fit fOR The Aged, or FORTA, criteria was developed in Germany in 2008 and was
later validated for use in 2012 (Curtin et al., 2019). Following FORTA’s validation, in 2015
FORTA was updated to combine the six European medication management lists into one large,
validated criteria, EURO FORTA (Curtin et al., 2019). The EURO FORTA criteria contains 264
medications and medication classes that are organized by clinical diagnosis or syndrome (Curtin
et al., 2019). Within each clinical diagnosis, the EURO FORTA criteria assigns a letter grade, AD, to each of the medications based on the safety and effectiveness in treating the particular
diagnosis or syndrome (Curtin et al., 2019). The grading scheme would allow the clinician to
ideally select the safest and most effective treatment while the medications that are harmful or
should be avoided are indicated and EURO FORTA provides the clinician an alternative (Curtin
et al., 2019). The EURO FORTA grading scheme is comprised of the following: “A, Absolutely,
indispensable, clear-cut; B, Beneficial, proven benefit but limited extent of effect or safety
concerns; C, Caution, questionable efficacy or safety profile, explore alternatives, and D, Don’t,
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avoid if possible, find alternative” (Curtin et al., 2019, p. 6). A significant downfall of the EURO
FORTA criteria is, unlike the STOPP/START or Beers Criteria, EURO FORTA does not address
any drug-drug or drug-disease interactions (Curtin et al., 2019).
There are a limited number of studies available which include EURO FORTA as a
measurement tool. In a 2019 study by Awad and Hanna across 10 primary healthcare centers in
Kuwait, they found that in a population of 420 participants, 53.1% of PIMs were identified by
Beers Criteria, 55.7% by STOPP, and 44.3% by FORTA.
2.2.3 PRISCUS List
The PRISCUS list is a lesser known list of potentially inappropriate medications for use
in elderly patients. Developed in 2010 by a group of German medical researchers after
identifying the need for a PIM list based on the drugs and medications that were available for use
within Germany and the differences in prescribing practices of its physicians (Holt et al., 2010).
A study by Amann et al. (2012) found that in a retrospective study of medical care given in 2007
to 804,400 elderly German patients that 25% of these patients were receiving at least one PIM.
Amann et al., (2012) discusses while further research and validation of the PRISCUS list was
needed, developing a PIM list containing specific medications available in Germany was
necessary. This PIM list was developed in a similar method as the other PIM listings discussed
thus far using a two round Delphi method utilizing a group of 25 expert participants (Holt et al.,
2010). After both Delphi evaluation rounds were complete, the expert panel agreed on the
inclusion of 83 drugs from 18 different classes to the PRISCUS list (Holt et al., 2010). There was
a subset of 46 of the 83 medications that the panel could not reach a clear decision of their
appropriateness, and like Beers, the decision was made to include this subset of medications on a
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separate list and if the PIM is absolutely necessary, recommendations for clinical adjustments are
provided (Holt et al., 2010).
The number of studies published in English on the effectiveness PRISCUS list
identifying PIMs are limited in comparison to the availability of studies for the other PIM lists.
One study by Siebert et al. (2013) compared the effectiveness of PIM identification in 308
elderly patients at a geriatric rehabilitation facility using PRISCUS, STOPP/START, and Beers
Criteria. The study found that the PRISCUS list found less than half as many PIMs as STOPP
(0.5 vs. 1.2 PIMs) but identified slightly more PIMs as Beers (0.5 vs. 0.4 PIMs)
2.3

Falls and Fractures in the Elderly Population
It is well understood through the literature that falls and fractures in the elderly

population, regardless of Beers Criteria medication exposure, are serious, yet unfortunately
common occurrences. Published polypharmacy literature has found that 60% of elderly patients
take 5 or more medications, while 20% of elderly patients take 10 or more medications (Scott et
al., 2012). This study by Scott et al. (2012) found that elderly patients who experience hyperpolypharmacy, which is the concurrent use of 10 or more medications, are at a 6x increase of
experiencing an injurious fall during their lifetime. Aside from physical effects, there are a
number of psychological effects on the patient that also occur with falls – such as loss of
confidence in walking, fear of an additional falls, or the fear of losing independent living (Chang
et al., 2011; Dionyssiotis, 2012; Hester & Wei, 2013).
To begin to understand the relationship between falls and fractures and elderly
populations, one of the pieces of early literature is a study by Weiner et al. (1998). This study
was of particular importance because this was one of the few early studies that investigated and
found a dose-response relationship between elderly patients using CNS-active medications and

16
their risk of falling. While this study had limitations bound to the convenience sample of 305
community-dwelling elderly male veterans, the risk of falls and fractures was still present
following a dose-adjusted relationship of the CNS-acting medications the sample patients were
taking.
Following the Weiner et al. (1998) study, a 2002 study by Neutel et al. found that elderly
patients taking multiple drugs were at a higher risk of experiencing an injurious fall and
investigated the presence of polypharmacy and hyperpolypharmacy in the elderly. This study
found an unadjusted risk of patients who were exposed to some level of hyper-polypharmacy
were at a 6 times higher risk of hospitalization than a patient taking less than 5 different
medications (Neutel et al., 2002). A 2013 study by Hammond and Wilson further investigated
polypharmacy and falls in the elderly after Neutel et al. (2002) and others. Hammond and Wilson
(2013) found that polypharmacy can be independently linked as a risk factor to falls and
hospitalizations in elderly individuals but a stronger link exists between the patient experiencing
a fall and the specific type of medication that the patient is taking.
The study by Tinetti et al. 2006 focused on the healthcare expenditure of a single fall
event and the burden than potentially preventable falls place on the United States healthcare
system. Tinetti et al. (2006) found that the average healthcare expenditure for a single fall event
was $24,330 while the overall healthcare burden caused by falls in patients over the age of 65
years old was in excess of $5.7 billion annually.
When examining the literature for studies that investigated the relationship between falls
in the elderly and the presence of varying comorbidities yielded broad results. To my knowledge,
none of the literature available focused on all 29 Elixhauser Comorbidity conditions as O’Neill
Roldan (2018) and this study had. Chiu et al. (2015) considered patients with certain diagnoses
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or comorbidities and their association with falls and fractures. This study found patients with an
anxiety diagnosis were 4.7 times more likely to experience a fall than those without such a
diagnosis. Chiu et al. (2015) considered different classes of medications in this study and found
an increase in benzodiazepine use with the study group of patients. R. Gelbard et al. (2014)
found 72.5% of elderly patients that experienced an injurious fall had at least one comorbidity.
Gelbard’s study was one of the very few I could find that specifically focused on non-ground
level falls – which are a type of fall defined as beginning with both feet on the ground. Gelbard
found that non-ground level falls are typically cause more injury and lead to a longer length of
stay.
The study by Ambrose et al. (2015) found that falls account for more than 85% of
fractures in the elderly. These fractures are commonly associated with impaired balance and gait,
polypharmacy, and a prior history of falls and typically involve the fracture of an already
osteoporotic bone. This study led to Allali et al. (2017) developing the GOOD initiative, “Gait,
Cognition, & Decline” to study gait speed in relation to a patients quality of life. As predicted by
the study’s hypothesis, gait speed was significantly associated with an increased risk of falls in
elderly individuals because the loss of balance and stability while walking.
2.3.1 Fall-Risk-Increasing Drugs (FRIDs)
In 2011, Kragh et al. coined the term “Fall-Risk Increasing Drugs”, or FRIDs. This
specific list is composed of six classes of medications identified from either previously published
literature or classified by the World Health Organization as drugs that increase fall risk in elderly
populations (Kragh et al., 2011). The specific medication classes are psychotropics,
cardiovascular, anticholinergics, antiepileptics, antiparkinsonian, and opioids medications There
are many medications which are routinely used in younger patients that are not safe for the
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elderly for a variety of different reasons ranging from drug-drug or drug-disease interactions to
physiological changes in the elderly as they age (Kragh et al., 2011).
2.3.2 Benzodiazepines
Benzodiazepine use in the elderly is common for a variety of reasons whether for sleep
disorders, anxiety, or other psychological uses. This class of medications are known to sedative
effects in regular adults and those sedative effects could be amplified in some cases in elderly
individuals. Ray et al. (2000) considered this topic of the sedative effects in community-dwelling
elderly individuals who still remained mobile and self-sufficient. Ray et al. (2000) echoes the
already understood risk of increased sedative effects and falls in elderly patients using
benzodiazepines but happened to be one of the earlier studies that considered falls and the actual
timing of starting a new benzodiazepine prescription. This study found the greatest risk of falls in
the elderly occur within the first seven days of beginning a new benzodiazepine prescription (OR
= 2.96) but still remained elevated after as time continued.
The Neutel et al. (2002) study mentioned earlier also found patients who were starting a
new benzodiazepine or antipsychotic prescription were at a very high risk of injurious fall.
Through the use of a case-crossover study, Neutel et al. (2002) found that these patients starting
a new course of benzodiazepine or antipsychotic medication treatment were at an 11 times higher
risk of falling in comparison to their control. Bogunovic and Greenfield (2004) investigated
benzodiazepine use in community-dwelling elderly who still operate motor vehicles. This study
found because of the sedative properties of benzodiazepines, their usage in the elderly must be
carefully monitored in those community-dwelling individuals still operating motor vehicles.
Benzodiazepines can contribute to psychomotor impairment due to their sedative effects; and
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while also increases the risk of falls in these individuals, may also increase the risk of automobile
accidents with those who may still operate motor vehicles.
2.4

Polypharmacy
While there is no strict descriptive or quantitative definition of polypharmacy, it is

generally described through the literature as the prescribing and administration of five or more
medications that are clinically indicated for a patient but may be a duplication treatment or even
unnecessary care for the individual (Dagli & Sharma, 2014; Endsley, 2018; Gokce Kutsal et al.,
2009; Hosseini et al., 2018; Wimmer et al., 2014). In various systematic reviews of the literature,
it was determined that the actual quantitative threshold for polypharmacy varied widely.
Jokanovic et al. (2015) found that most studies in the review used 5 or more, 9, or 10
medications as the threshold for defining polypharmacy while Masnoon et al. (2017) found that
the most common qualitative definition was 5 or more medications, but this also varied widely
between two medications to 11 or more. One important distinction that Masnoon et al. (2017)
makes in their literature review is that a pure numerical definition of polypharmacy should not be
enough in making clinical decisions. Masnoon et al. (2017) argues that polypharmacy simply as
an integer count does not take into consideration one important aspect, the pharmacology of the
patients’ medications along with the clinical needs of the patient. This argument for considering
the actual clinical relevance of the medications and the patients’ comorbidities is important
according to Masnoon et al. (2017).
Considering this point by Masnoon et al. (2017), the definition of polypharmacy would
only count the number of duplicate or harmful medications prescribed to the patient, not the
medications that, while they might be listed as a PIM, are providing an overall positive clinical
benefit to the patient. This is a valid point because the guidelines, Beers Criteria,
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START/STOPP, and the others, are meant to provide high-level guidance for the clinician.
Masnoon et al. (2017) presents the need for tools that consider polypharmacy, but also consider
the patient as a whole to provide a more individualized approach to their medication
management and eliminating harmful or unnecessary medications from their regimen.
In a recent report published by the Centers for Disease Control (CDC), the percentage of
both males and females taking at least one, three or more, and five or more prescription
medications has been steadily on the rise since 1988, see figure 2.3.1 (National Center for Health
Statistics, 2019). Given prescription drug use across all genders and age brackets continues to
rise, we can infer that the prevalence of adverse drug events, or ADEs, across all individuals also
has the potential to increase.
Figure 2: Prescription drug use within 30 days, both sexes

(National Center for Health Statistics, 2019)
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In a 2005 systematic review of the literature, Fulton and Allen studied polypharmacy as a
general topic in the care and treatment of elderly patients. The outcomes of the Fulton and Allen
(2005) study are an excellent summarization of the status of the literature on polypharmacy at
that time but what is most beneficial are the areas for future research and the gaps in the
literature that are noted. For example, Fulton and Allen (2005) notes that the utilization of
computerized medication databases or electronic health record (EHR) systems as done in many
European studies, removes the reliance on the patient to recall all of their prescriptions. Use of
and EHR would also allow for the automation of different medication management tasks and
would also allow physicians and hospitals to implement the different criteria sets into their
clinical decision support systems (CDSS). Second, and most importantly, Fulton and Allen
(2005) notes an important point in there is still no generally accepted definition on what
constitutes polypharmacy. Fulton and Allen (2005) believes that the definition of polypharmacy
should be based on clinical indication and whether or not the prescribed medication is
appropriate for the patient, while other studies (Jokanovic et al., 2015; Olson et al., 2014) believe
that the definition of polypharmacy should be quantitative in nature.
2.4.1 In regards to Potentially Inappropriate Medications
One of the most important considerations with polypharmacy and the aging and elderly
population is polypharmacy with the involvement of potentially inappropriate medications, or
PIMs. Beers Criteria, STOPP/START, EURO FORTA, and others all make attempts to reduce
the number of PIMs prescribed to elderly patients.
A 2015 study of 124,051 Medicare beneficiaries by Lund et al. found that while
interventions such as the ones noted above have displayed up to an 80% reduction in PIMs
prescribed to elderly patients either at the point of care or through deprescribing, a significant
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increase of PIM use in an in-patient setting was still displayed from admission to discharge.
Lund et al. (2015) found that within their study population 7.7% of patients were prescribed a
PIM on admission to the hospital and that number increased to 8.6% upon discharge.
In an Australian study by Price et al. (2014b), they examined the potential association
between the exposure to PIMs on the Beers Criteria and unplanned hospitalizations in 251,305
elderly Western Australians. Price et al. (2014b) found that there was a direct correlation
between overall PIM exposure and an elevated risk of unplanned hospitalizations. Price et al.
(2014b) also found that the number of different PIMs taken and the quantity were also associated
with an elevated risk of unplanned hospitalizations. In their study, 15% of unplanned
hospitalizations of all patients in the study population has been due to PIM exposure and an
ADE. The findings by Price et al. (2014b) support the theory of the number of PIM exposures a
patient has, the greater their risk of an unplanned hospitalization.
2.4.2 In regards to Adverse Drug Reactions and Events
A serious consequence of polypharmacy are adverse drug reactions or events (ADR or
ADE). The Institute of Medicine defines adverse drug events as an injury to a patient resulting
from any medical intervention related to a drug while adverse drug reactions are defined as an
event in which a patient experienced harm caused by a drug when taken at normal doses
(Institute of Medicine, 2000). In a perfect world, medications designed to cure or alleviate
diseases would do just that and not cause further harm or pain to the individual. Unfortunately,
though, this is not the case. Every individual is different and unique in their own genetic way
which means that every pharmaceutical has the potential to have a slightly different
pharmacological action when taken.
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Research has shown in an in-patient setting, ADEs comprise one-third of all hospital
adverse events causing an average length of stay increase from 1.7 to 4.6 days, and accounts for
more than 2 million hospital stays per year (US Department of Health and Human Services
Office of Disease Prevention and Health Promotion, 2014). Additional research has also shown
that in an out-patient setting, ADEs cause an estimated 1 million annual emergency department
(ED) visits, 3.5 million physician or primary care office visits, and 125,000 hospital admissions
annually (US Department of Health and Human Services Office of Disease Prevention and
Health Promotion, 2014). Curtin et al. (2019) reports that ADEs contribute directly to 6-17% of
all hospital admissions for older adults and are commonly overlooked in the elderly population.
This is because ADEs commonly manifest themselves as common, nonspecific symptoms such
as fatigue, constipation, confusion, and falls; all of which as generally prescribed to the aging
process or “just getting old” (Curtin et al., 2019). Curtin et al. (2019, p. 2) made a feasible
observation in their systematic review that “any new symptom in an older patient should be
considered a drug side effect until proven otherwise.”
Research in the area of polypharmacy and adverse drug events is very expansive in
nature. A 2001 study by Hohl et al. found that in a population of 283 patients taking on average
4.2 medications per person, ADEs accounted for 10.6% of emergency department admissions
within that patient sample. In an 11-year analysis by Bourgeois et al. (2010), they found that
ADEs result in more than 100,000 hospital admissions annually with elderly patients being at the
highest risk of hospitalization. In a 2012 British study by Calderón-Larrañaga et al. found that
within a multicenter observational study of 79,089 patients polypharmacy was one of the risk
factors [OR = 1.34] for an ADE and later subsequent hospital admission.
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2.4.3 In regards to Long-Term Care Facilities
Consideration also needs to be given to elderly patients whom are no longer independent
and reside in long term or assisted care facilities. These patients are more than likely to be taking
more than one prescription medication, have decreased mobility increasing their susceptibility to
falls and injuries, and may have cognitive impairment such as dementia (Jokanovic et al., 2015;
Murray et al., 2004). The elderly and aging populations also pose unique clinical challenges
when it comes to their treatment and care. For example, this group of patients typically also have
physiological changes that cause different medications to absorb or excrete at different rates
(Gokce Kutsal et al., 2009).
Research has also shown that the involvement of clinical pharmacists in a medication
review or reconciliation process in long-term care facilities has decreased not only the overall
number of prescriptions for a patient, but the number of inappropriately prescribed medications
and adverse drug events, too (Thiruchelvam et al., 2017).
2.4.3.1 Complexity of medication regimens.
Jokanovic et al. (2015) presented administrative challenges in his study with regards to
polypharmacy in long-term care facility patients and their medication regimens. Because of the
additional number of medications that these patients require, there is a need for the appropriate
number of employees in the workforce to support and care for their residents (Jokanovic et al.,
2015). In 2009, Mitty performed an online survey of all members of the key assisted living
professional organizations inquiring about their medication administration practices. She found
that more than half of the “assisted living residences” (ALRs) administered medications to
between 80 to 100% of their residents and that almost half of these ALRs use unlicensed
assistive personnel, or medication aids, to administer said medications to their residents (Mitty,
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2009). Through a policy review, Mitty (2009) also found that only 14 states require that a
licensed nurse administer medications and 32 states permit these unlicensed assistive personnel
to administer medications. Unlicensed assistive personnel do not have a deep level of clinical
knowledge that should be required in administering medications, especially to a vulnerable
population such as the elderly. This is worrisome due to the fact that fewer than 10 states require
the reporting of a medication error or adverse drug event to the patients resident physician
(Mitty, 2009).
This point is of specific discussion from an Australian study by Wimmer et al. (2014).
This study took a specific look at an elderly patient’s medication regimen on discharge and rated
its complexity using the Medication Regimen Complexity Index (MRCI). Wimmer et al. (2014)
found patients who had complex medication regimens upon discharge to their home or family
had no association in future unplanned hospital admissions. Whereas patients with complex
medication regimens who were discharged to a non-home or long-term care facility had a higher
chance of an unplanned hospital admission based on the number of discharge medications and
the presence of polypharmacy (≥ 9 medications) (Wimmer et al., 2014).
On this topic, Mitty (2019) recommends that the medication aide or medication
technician certification that only a few states offer to unlicensed ALR personnel should be
regulated and required across the country. Not only would this provide an opportunity for
training on proper medication administration and the identification of ADEs, but could also
mimic the Medical Assistant certification and be one of the first stepping stones for individuals
to possibly further their career or education.
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2.4.4 The Prescribing Cascade Effect
A cause and an effect of polypharmacy is a concept called a prescribing cascade. A
prescribing cascade is a clinical term that begins when healthcare providers misinterpret a newly
presenting symptom or an ADE from interacting medications as an entirely new symptom of a
disease and in turn, prescribes another medication to the patient (Kalisch et al., 2011; Piggott et
al., 2020). The concept of prescribing cascades, their causes and effects, as well as their clinical
implications have come under a new light with the growing problem of polypharmacy (Brath et
al., 2018; McCarthy et al., 2019). The patients that are most at risk for prescribing cascades are
those with multimorbid conditions and those reliant on others for their care and wellbeing, the
elderly (Kalisch et al., 2011). Certain classes of medications either when mixed with other
medications, or if certain conditions are present in the patient, the adverse effect of the added
medications can become synergistic and amplified all while the physician was trying to provide
relief to the patient from the first medication’s side effect (Kalisch et al., 2011). For example,
Brath et al. (2018) describes one of the most well-known prescribing cascades identified almost
30 years ago which linked nonsteroidal anti-inflammatory drugs (NSAIDs) to the development
of hypertension and the later prescription of anti-hypertensive medications (Brath et al., 2018).
Potentially not 30 years ago, but the identification of this cause, effect, and treatment could have
saved the patient trips to their physician’s office and lessened the amount of healthcare resources
utilized.
Prescribing cascades are a serious consequence of polypharmacy, especially given the
rate at which polypharmacy is seen in elderly, vulnerable populations (McCarthy et al., 2019).
Kalisch et al. (2011) described a scenario where a more than common prescribing cascade took
place; an elderly patient was recently prescribed an ACE-inhibitor developed a cough and was
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later prescribed a codeine-based cough product, as the cough persisted the patient was then
prescribed an antibiotic which in turn caused the patient to develop Clostridium difficile diarrhea,
which later caused their hospitalization. This scenario caused an undue amount of harm to the
patient, caused an unplanned and unnecessary hospitalization, which could have potentially led
to the death of the patient. The most common medication classes that are typically found to be
involved with prescribing cascades are drugs for dementia, antihypertensives, sedatives, opioids,
NSAIDs, antiepileptics, antibiotics, and medicines for nausea (Brath et al., 2018; Kalisch et al.,
2011). All these medication classes are coincidentally found on the Beers Criteria,
STOPP/START, and other lists of potentially inappropriate medications. Strategies for
interrupting prescribing cascades and polypharmacy are discussed later in this chapter.
2.4.5 Strategies for Reducing Polypharmacy
The primary strategy of reducing polypharmacy in not only elderly patients, but all
patients, is called “deprescribing.” Deprescribing is defined by Scott et al. (2015, p. 827) as “the
systematic process of identifying and discontinuing drugs in instances in which existing or
potential harms outweigh existing or potential benefits within the context of an individual
patient’s care goals, current level of functioning, life expectancy, values, and preferences.” The
goal of deprescribing is not to change treatment plans at will on a patient but to provide the
patient the safest and most effective method of treatment for their condition. When performed
appropriately for the drug or medication being deprescribed, as shown by a literature review by
Scott et al. (2015), is a safe practice and often provides benefit to the patient in terms of reduced
costs, medication burden, and decreased risk of various interactions or unplanned
hospitalizations.
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Scott et al. (2012) developed a 10-step conceptual framework for pharmacists and
clinicians to accomplish two primary goals, first, to select the proper drug based on the patient
and clinical indication, and second, reduce the number of inappropriate medications prescribed to
the patient. Each step of the framework presented by Scott et al. (2012) was based on literature
reviews and presented for use in a stepwise sequence. Shortly after in 2015, Scott et al. revised
the framework into a condensed five steps:
•

“(1) ascertain all drugs the patient is currently taking and the reasons for each one;

•

(2) consider overall risk of drug-induced harm in individual patients in determining
the required intensity of deprescribing intervention;

•

(3) assess each drug in regard to its current or future benefit potential compared with
current or future harm or burden potential;

•

(4) prioritize drugs for discontinuation that have the lowest benefit-harm ratio and
lowest likelihood of adverse withdrawal reactions or disease rebound syndromes; and

•

(5) implement a discontinuation regimen and monitor patients closely for
improvement in outcomes or onset of adverse effects” (Scott et al., 2015, p. 829)

Using new and advanced technological measures discussed later in this chapter, the
framework developed by Scott et al. (2012) could easily be streamlined into a useful clinical
utility once the framework itself is validated for use.
Research in this area has shown with successful attempts at reducing polypharmacy and
the number of medications prescribed to a patient. A 2010 study by Garfinkel and Mangin
applied the Good Palliative-Geriatric Practice algorithm to a sample of 70 elderly patients in an
attempt to reduce polypharmacy and the “medication burden” on these patients (Garfinkel &
Mangin, 2010, p. 1648). Using this algorithm, Garfinkel and Mangin (2010) recommended the
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discontinuation of 311 medications in 64 of the 70 participants, an overall 81% reduction in
polypharmacy with no reported significant adverse drug events due to the discontinued
medications.
Another strategy for decreasing polypharmacy was developed by Drenth-van Maanen et
al. (2009) called the Prescribing Optimization Method or POM. The POM was designed to assist
family and general medicine physicians reduce the amount of polypharmacy on their elderly
patients through 6 guided questions:
•

“Is undertreatment present and addition of medication indicated;

•

Does the patient adhere to his/her medication schedule;

•

Which drug(s) can be withdrawn or which drugs(s) is/are inappropriate for the
patient;

•

Which adverse effects are present;

•

Which clinically relevant interactions are to be expected; and

•

Should the dose, dose frequency and/or form of the drug be adjusted” (Drenth-van
Maanen et al., 2009, pp. 690-691)

To test the efficiency of the newly designed POM tool, Drenth-van Maanen et al. (2009)
first asked 45 physicians to review and deprescribe medications from two patients randomly
selected from a pool of ten. Following this, the group of physicians were trained on the POM
framework and optimization process then asked to perform the review and deprescribing process
again on the same case. What Drenth-van Maanen et al. (2009) found was an increase in
appropriate prescribing optimization from 34.7% pre-POM training to 48.1% post-training.
Overall, the POM framework significantly increased valid deprescribing decisions in complex
multimorbid elderly patients (Drenth-van Maanen et al., 2009).
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2.4.5.1 ARMOR.
In 2009, Dr. Raza Haque, MD developed the ARMOR tool to address the growing
problem of polypharmacy seen in long-term care facilities. The ARMOR tool has five
components, Assess, Review, Minimize, Optimize, and Reassess, and when implemented and
used properly will consider not only the patient’s pharmaceutical profile, but their clinical history
and their overall functional status (Haque, 2009). The first implementation of the ARMOR
protocol was after its development by Haque (2009) in a long-term care facility using an
interdisciplinary team of medical professionals to target geriatric admissions and those patients
with frequent falls. This interdisciplinary team consisted of a medical director, director level
nursing staff, occupational and recreational therapists, social workers, and pharmacists (Haque,
2009). The ARMOR process for managing polypharmacy begins with a regular review and
analysis of the patient’s charts to examine dosing as well as the presence of inappropriate
medications (Haque, 2009). The team members would then report on their subjective and
objective observations of the patient as well as any proposed changes to their current medication
regimen (Haque, 2009). After a consensus was reached for each patient’s profile, the facilities
medical director would discuss the team’s recommendations for modifications to the patient’s
care (Haque, 2009).
The ARMOR tool for reducing polypharmacy was effective in significantly reducing
polypharmacy, the cost of care, and the number of hospitalizations from patients within the
specific long-term care facility (Haque, 2009). Haque (2009) also found that the ARMOR tool
reduced the number of falls and patient behaviors that may lead to self-harm. Given the results of
ARMOR’s first use, Haque (2009) expanded the scope of included patients to those receiving 9
or more medications and those admitted for rehabilitation. Haque (2009) found significant
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improvement in the facilities quality indicators (QI) tracked by the facility in comparison to their
state and national averages. In a follow-up study by Haque and Alavi (2019) found that utilizing
ARMOR with an interdisciplinary team saw a significant reduction in the number of
psychotropic medications prescribed to LTC patients within the study’s facility. This finding is
particularly important because psychotropic medications have been shown to have a significant
association with falls in elderly patients (Huang et al., 2012). Studies have shown that falls are
not only one of the leading causes of elderly hospitalizations and healthcare expenditures, but
happen to also be one of the leading causes of morbidity and mortality in elderly patients with
multiple co-morbidities (Rondi Gelbard et al., 2014; Huang et al., 2012).
2.4.5.2 The Brown Bag Method.
The brown bag method or brown bag approach is a well employed method for reducing
polypharmacy in various clinical settings. The brown bag method is a medication review process
where the patient collects all their medications including prescriptions, over-the-counter
medications, vitamins, and herbal supplements together and brings them into their next provider
appointment (Dovjak, 2012; Kim & Parish, 2017). The goal of the brown bag method is to
review all of the patient’s medications, identify medications that can be discontinued,
medications or supplements that could be causing interactions, reconcile the patient’s “brown
bag” with the medications listed in their medical record, and to educate the patient on their use of
their medications (Kim & Parish, 2017). Studies have shown this to be an effective method of
not only reducing the number of medications the patient is taking, but reducing the number of
potential adverse drug events as well.
In a 2015 study by O’Connell et al., found in a population of 85 patients in a convenience
sampling from a senior center, that 40% of the patient’s drug-related problems were due to
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inappropriate drug selections on behalf of the prescriber, and 23% due to inappropriate doses
being prescribed to the patent. The study found due to the patient’s level of comfort with the
brown bag review process begin able to talk and ask questions in a comfortable environment,
63% of the recommendations made by the clinical staff were implemented by the participants
(O'Connell et al., 2015). Interestingly, a 2004 study by Williams et al. found that the patients
who participated in a randomized control trial to receive a brown bag medication review that
most patients who participated and received suggested changes to their medication regimens
were hesitant to make such changes. Williams et al. (2004) cite one of the reasons why patients
may have been resistant to the suggested changes because their primary physician was not
directly involved in the medication review process. Williams et al. (2004) found that only 33%
of the time, patients who were involved in the medication review process accepted the
recommendations of the reviews only after they were told their primary physician was informed
of and approved the recommended changes. In a similar type study by Garfinkel (2017) found
that in some cases it’s not the patient that is resistant to the change in regimen, it’s the physician
themselves.
2.4.6 Addressing Polypharmacy in the Primary Care Setting
One area lacking in the literature regarding polypharmacy is addressing the topic at one
of the initial points of contact, the primary care setting. Especially in the elderly population,
building a strong patient-physician relationship is crucial. Studies on the topic dating back to
1996 emphasize this point and the physician should lay the ground work starting with the initial
meeting with the patient (McCormick et al., 1996). A 2015 literature review confirmed a known
gap in the literature, the need for standardized strategies in addressing polypharmacy in the
primary care setting and the effects of these interventions on patient outcomes. Nevertheless,
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addressing polypharmacy in any way possible is important on behalf of the patient overall care
and wellbeing.
2.5

Predicting Readmissions
We have shown there is an understanding of how Beers Criteria, different potentially

inappropriate medications, adverse drug events, and unplanned hospitalization rates are all
associated with each other through different studies in the literature. Researchers have begun to
take the information they have learned and the data they have available to them in attempts to
build a model able to predict a future hospital admission or indicate a patient may be at risk for a
future hospitalization. There is a vast amount of literature on the topic of predicting readmissions
but we have found that many published studies are focused on a specific disease state or chronic
condition. For example, a 2016 study by Tandon et al. attempts to predict unplanned
hospitalizations in patients with cirrhosis, a 2014 study by Manzano et al. attempts to determine
patterns and predictors of unplanned hospitalizations in elderly patients with GI cancer, or a
2019 study by Rothenberg et al. attempting to predict unplanned admissions after elective
outpatient surgery. There are very few pieces of published literature that use Beers Criteria
medications, or other PIM lists, in an attempt to build a prediction model for unplanned
hospitalizations.
A 2014 study by Louis et al. displays an attempt at building a risk of hospitalization
prediction tool in 3,726,380 adults over the age of 18 in a specific region of Italy. While this
study is not specific to elderly patients, the outcomes are substantial and should be discussed.
The prediction model built by Louis et al. (2014) was able to predict hospitalizations in the
cohort of patients with a c-statistic of 0.856 overall. This specific model took into consideration
the patient’s age, gender, demographics, healthcare utilization, cardiovascular disease, diabetes,
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chronic renal failure, a history of cardiovascular medications, and the presence of polypharmacy;
all variables used by Louis et al. (2014) are also available in the dataset for this study (Louis et
al., 2014). Louis et al. (2014) also tested their 2012 prediction model built from 2011 data on
data available from 2010 to build a 2011 prediction model. Louis et al. (2014) found between the
two year’s models built, there was only a slight change in c-statistic (2011 = 0.853, 2012 =
0.856). This indicated to Louis et al. (2014) the model build can be used on future data as it
becomes available and provide reliable results.
A second readmission prediction tool, the 80+ Score, which takes into consideration
patient demographics as well as their pharmacologic data as well (Alassaad et al., 2015). The
80+ score was built and internally validated against a sample of 368 elderly patients who were 80
years or older from a Swedish university medical center (Alassaad et al., 2015). The 80+ score
and the study by Alassaad et al. (2015) is one of the first studies to include the patients’
medication history as one of the potential indicators or causes for an unplanned hospital
readmission. The final model for the 80+ score by Alassaad et al. (2015) included the following
risk factors: eGFR separated into for levels of kidney function, social support (i.e. discharge
location, nursing home vs. family home), presence of pulmonary diseases (asthma or COPD),
presence of malignant diseases, use of prescription drugs for peptic ulcers or GERD, use of
prescription opioids, and use of prescription non-TCA-antidepressants. The 80+ score is based
on a point-scoring system and is presented in figure three. The 80+ score, to my knowledge at
the time of this writing, is the only prediction model for unplanned hospitalizations that includes
a patients prior pharmaceutical history with a c-statistic >0.7, at 0.72 (Alassaad et al., 2015).
While the 80+ score is only internally validated, Schwab et al. (2019) make reference to the
prediction model and the potential necessity to externally validate it for greater use.
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Figure 3: Data used for the 80+ point scoring system

(Alassaad et al., 2015, p. 3)
An additional prediction model built by LaMantia et al. (2010) was able to produce a cstatistic of 0.73 when the model included age, triage score, heart rate, diastolic blood pressure,
and the patient’s chief complaint. This model is different than the goal of this study though,
LaMantia et al. (2010) built a model in an attempt to streamline hospital admissions for elderly
patients presenting directly to the ED, not to predict unplanned hospitalizations. LaMantia et al.
(2010) attempted to further extrapolate their model attempting to predict another ED visit 30
days post-discharge in the same population of elderly patients, this modeling attempt also failed
the c-statistic threshold. LaMantia et al. (2010) attributed the inability to build such a prediction
model to the high rate of return in elderly patients to emergency departments ranging from their
chronic medical conditions, to inadequate primary care availability, to the patient’s social or
psychological characteristics.
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Other attempts at building prediction models for unplanned hospitalizations have not
been as successful as the 80+ score by Alassaad et al. (2015). A study by Parameswaran Nair,
Chalmers, Connolly, et al. (2016) attempted to build a prediction model they called the
Prediction of Hospitalization due to Adverse Drug Reactions in Elderly Community-Dwelling
Patients, or PADR-EC. This model was built off a patient sample of 768 patients aged 65 years
or older with admission to two specified Italian hospitals. Parameswaran Nair, Chalmers,
Connolly, et al. (2016) found that even with 92.2% of the total admissions (n = 115), their model
to predict hospitalization in these patients only yielded a ROC c-statistic of 0.70 which decreased
to 0.67 in a later validation sample of patients.
2.5.1 In regards to Adverse Drug Events
In a 2015 German study by Henschel et al., they sought to understand the hospitalization
rates for 647,073 patients aged 65 years or older as of the year 2010 and received a PIM as
indicated by the German PRISCUS list of inappropriate medications. Henschel et al. (2015) used
propensity score matching to build a control group of patients at an equivalent risk level but who
did not receive any of the medications on the PRISCUS list. Despite using a different PIM
criteria list local to Germany, the outcome of this study echoes what is seen already through the
literature. Henschel et al. (2015) found patients in the PIM group experienced more ADEs and
had a higher chance of hospitalization when compared to the non-PIM control group.
In a 2017 study by Shapiro et al. studying high-risk medications in 717 frail elderly
patients in a long-term care facility, having more than more than four medications doubled the
risk of readmission within 30-days of their initial discharge. The patients in the Shapiro et al.
(2017) study though, have a much higher mean count of medications per person (14.1) and a
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higher mean Charlson comorbidity index score (≥6) than seen in other published literature thus
far.
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3) CHAPTER III METHODOLOGY
As previously mentioned, the data used in this study is the dataset used by O’Neill
Roldan’s (2018) study, Effect of Beers criteria on healthcare utilization and costs in communitydwelling elderly patients. The initial patient sample was extracted from the 2013 edition of the
Truven Health Marketscan® Commercial Claims and Encounters Database purchased by and
housed at the Comparative Effectiveness & Data Analytics Research Resource (CEDAR) at the
Medical University of South Carolina, Charleston, SC. All statistical analysis performed using
SAS 9.4 (Cary, NC) at α = 0.05.
3.1

Original Data Use by O’Neill Roldan (2018)
O’Neill Roldan’s 2018 retrospective cohort study identified patients 65 years and older,

who were community-dwelling patients, and were observed taking a medication present on the
Beers Criteria during the selected baseline period of January 1, 2013 – March 31, 2013 (n=
3,512,540) from within the 2013 edition of the Marketscan® database. Once the initial patient
sample was extracted, O’Neill Roldan grouped the patients based on those whom had taken at
least one medication on the 2012 revision of the Beers Criteria and those who had not (n=
1,297,636 vs. 2,214,904), this step is crucial in the preparation of the propensity score matching
process. Because the Marketscan® database contained commercial claims, the study was not
limited to only the claims submitted to Medicare but was able to include those elderly patients
that had commercial insurance to supplement their existing Medicare plan (O’Neill Roldan,
2018).
To select patients to place in the experimental, or Beers Criteria, arm of the study,
O’Neill Roldan (2018) needed to translate the list of potentially inappropriate medications on the
Beers Criteria into their individual National Drug Code (NDC), including secondary codes such
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as packaging type or packaging quantity changes. The NDC is comprised of three components,
first the labeler or manufacturer identifier, second the product code which identifies the strength,
dosage form, and formulation, and third the package code to distinguish between different sizes
and types (U.S. Food and Drug Administration, 2019). O’Neill Roldan (2018) reported that the
138 medications on the Beers Criteria were converted to a total of 73,644 NDC codes to identify
the patients needing to be included in the experimental arm of the study. Inclusion into the
control arm of O’Neill Roldan’s study required the absence of any of the NDC codes identified
as being a PIM on the Beers Criteria.
Once O’Neill Roldan (2018) constructed the two sample groups, the study then built a
Charlson Comorbidity Index score and a frailty index score which was then subdivided into three
dichotomous variables, robust, pre-frail, and frail. O’Neill Roldan (2018) also included a
dichotomous variable to indicate if the patient had any type of hospital admission during the
selected baseline period. O’Neill Roldan also used information from outpatient visits to construct
an Elixhauser Comorbidity Index score as well as a dichotomous variable for 26 of the 29
Elixhauser conditions indicating their presence for each patient in the dataset, see table 3. As an
extension from the Marketscan® database, O’Neill Roldan (2018) was also able to leverage the
information contained within the Marketscan® database to calculate the patient’s total inpatient,
outpatient, and prescription medications costs as well. Because the Marketscan® database
included prescription drug data and claim information, this was one of the primary reasons
O’Neill Roldan (2018) selected this data source.
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Table 1
Elixhauser Comorbidity conditions included and excluded
Included
Asthma
Cardiac Dysrhythmias
Chronic Obstructive Pulmonary Disease
Chronic Renal Failure
Conduction Disorders of the Heart
Congestive Heart Failure
Cystic Fibrosis
Diabetes with and Without Chronic
Complications
Diverticulosis and Diverticulitis
Epilepsy
Heart Valve Disorders
Hepatitis
HIV Infection
Hypertension
Multiple Sclerosis
Otitis Media (Middle Ear Infection)
Parkinson’s Disease
Pericarditis
Endocarditis and Myocarditis
Pulmonary Heart Disease
Rheumatoid Arthritis
Schizophrenia
Senile
Sickle Cell Anemia
Systemic Lupus Erythematosus
Vertigo

Excluded
Chronic Ulcers of the Skin
Late Stroke
Paralysis

(O'Neill Roldan, 2018)
The treatment and control sampling methodology from O’Neill Roldan (2018) is
presented in figure 3.1.1 below.
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Figure 4: Treatment and Control Sample Design

(O'Neill Roldan, 2018)
With the selection and grouping of the patient sample based on the presence of any Beers
Criteria medications, O’Neill Roldan (2018) could then begin the propensity score matching
process between the two patient groups. Propensity score matching is the process of assigning a
score to a subject in an observational or retrospective study equaling the conditional probability
of that subject being included in the treatment arm of the study (Austin, 2011; Gant & Crowland,
2017). Propensity score matching allows researchers to reduce confounding between variables
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and allows for observational or retrospective types of studies to mimic the structure of a
randomized control trial (Gant & Crowland, 2017). O’Neill Roldan (2018, p. 81) used the
following variables to match patients in both arms of the study: “age, gender, geographic region,
hospital admission, member days [days insured], frailty, Charlson Comorbidity Index, and the 26
Elixhauser Comorbidity Indicators.” Through the use of these matching variables, O’Neill
Roldan (2018) was able to complete a 1:1 propensity score match between all 1.297 million
patients in the Beers arm of the study to 1.297 million patients in the control arm. Those patients
in the control arm of the study were removed from the data set if they were not matched to a
patient in the experimental arm of the study.
A data dictionary containing the variables and descriptions from the data used by O’Neill
Roldan (2018) is available in Table 18.
3.1.1 Propensity Score Matching
Many studies that examine the relationship between PIMs and unplanned hospitalizations
utilize a statistical method called propensity score matching. Propensity score matching is the
process in which a study is able to mimic randomization between a control and experimental
group when using retrospective data or if the study has already begun without randomization
taking place (Henschel et al., 2015). The propensity score matching process allows researchers to
directly compare the effect of an intervention on two groups of participants in the matched
sample (Austin, 2011).
3.2

Research Design and Secondary Use of Data Set
Our study is a retrospective cohort study using propensity-score matched patients in a

Beers Criteria medication exposed and non-exposed group. The Beers Criteria classification and
propensity-score matching was performed by O’Neill Roland (2018) and augmentations of that
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dataset would be necessary to fit the purposed of this study. The first set of data augmentations
needed required the extraction of data for hospital admissions and emergency department visits
for the specific ICD-9 codes for falls and fractures, and confusion and delirium. To achieve this,
the patients ENROLID was matched back to the original MarketScan® data set and the primary
ICD-9 code for the admission was identified. The presence of an ICD-9 code for falls present in
Table 2 was indicated in the dataset as (falls=1) and the presence of an ICD-9 code for confusion
and delirium admissions present in Table 3 was indicated in the dataset as (dill=1). These
dichotomous variables were set to “0” if the primary ICD-9 code for the admission was not
present in the inclusion list.
Within the augmented dataset was created drug sub-group specifications for the specific
medication classes associated with falls, delirium, and confusion and a residual group named
“Other Beers Drugs” to capture the use of any other Beers Criteria medication not specific to a
named medication class. These Beers Criteria indicator variables are discussed in more detail in
section 3.2.2 below. The final dataset contained roughly 2.6 million patients and through the
propensity score matching by O’Neill Roldan (2018), this dataset had 1,297,627 patients who
took any Beers Criteria medications during January – March 2013 and an equal amount of
patients who took no Beers Criteria medications in January – March 2013.
3.2.1 Indicator Variables
To identify and construct indicator variables for falls and fractures, this study selected
ICD-9 “E” codes – “E” for external causes of injuries and poisonings. Listed in Table 2, the
selected ICD-9 codes for falls and fractures ranged from accidental falls from stairs or steps,
slipping, tripping or stumbling, to fractures. The same procedure was performed for confusion
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and delirium admissions. Listed in Table 3, this study considered drug-induced delirium,
subacute delirium, reactive confusion, psychoses, hallucinations, and altered mental status.
Table 2
List of ICD-9-CM codes for identification of falls
E Code
E880
E881
E882
E883
E884
E885
E886
E887
E888

Code Description
Accidental fall on or from stairs or steps
Accidental fall on or from ladders or scaffolding
Accidental fall from or out of building or other structure
Accidental fall into hole or other opening in surface
Other accidental falls from one level to another
Accidental fall on same level from slipping tripping or stumbling
Fall on same level from collision, pushing, or shoving, by or with other person
Fracture, cause unspecified
Other and unspecified fall

Table 3
List of ICD-9-CM codes for identification of delirium
ICD-9 Code
292.81
293.0
293.1
298.2
298.9
780.1
780.97

Code Description
Drug-induced delirium
Delirium due to conditions classified elsewhere
Subacute delirium
Reactive confusion
Unspecified psychosis
Hallucinations
Altered mental status

The presence of either a fall or fracture ICD-9 “E” code, or a confusion or delirium ICD9 code was indicated in the dataset using the “Falls” or “Dill” indicator variable. The value of 1
indicated the presence and the value of 0 indicated the absence.
3.2.2 Selected Beers Criteria Medication Classes
Following the creation of the falls and delirium admission indicator variables, two
categorical variables were created to indicate the Beers Medication class present for the patient.
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Table 4 indicates the Beers Criteria medication classes selected for falls and fractures and Table
5 indicates the Beers Criteria medication classes selected for confusion and delirium.
Table 4
Selected Beers Medication classes for falls and fractures
Medication Class
Antipsychotics
Barbiturates
Benzodiazepines
Sedatives
Tricyclic antidepressants

Label
APsyco
Barbit
Benzo
Sedativ
TCA

Table 5
Selected Beers Medication classes for confusion and delirium
Medication Class
Antihistamines
Antipsychotics
Benzodiazepines
Narcotics

Label
AHist
APsycho
Benzo
Narcoti

All other Beers Criteria medication classes were indicated using an “OtherBeers”
category. If the patient was not exposed to any Beers Criteria medications, they were indicated
using the “NoBeers” category.
3.3

Statistical Analysis
To begin the statistical analysis of this dataset, we will begin by determining the

frequency of the categorical variables and the means and standard deviations of the continuous
variables to build a patient descriptive characteristics table grouped by the Beers Criteria
medication indicator (AnyBeers). Significant differences between the two groups will be
determined using Pearson Chi-square tests for categorical variables and either Nonparametric
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methods, such as the Mann-Whitney U two-sample test, or using independent-samples t-tests for
non-normally and normally distributed continuous data, respectively.
Once the most frequent conditions are identified in the dataset, we will then be able to
study the association between various Beers Criteria medication classes these patients are taking
and the presence of hospital admissions. Significance between these categorical variables will be
determined using the Pearson Chi-square test, Elixhauser conditions that show significant
differences between the two patient sample groups will be identified and used as a starting point
for further analysis. Based on the specific Elixhauser conditions that are selected to build models
for, we will construct sub-tables to show the specific patient demographics for the selected
Elixhauser conditions.
Once associations are determined and ranked based on statistical significance, we then
used a multiple regression model to control for the variables to determine which in our dataset
would contribute significantly to a model. The regression models will consider the 26/29
Elixhauser conditions, patient demographics, frailty measures, and the patient’s calculated
Charlson Comorbidity Index score. A gamma log-linked regression model will be used to
determine costs for each of the selected Beers medication classes for inpatient, outpatient, and
pharmacy Rx specific costs as well as an estimated total study cost as compared to the NoBeers
baseline costs.
3.4

Protection of Human Subjects
This study is exempt from the MUSC Institutional Review Board processes as the data

analyzed does not meet the criteria for human subjects as per the definition contained in the
MUSC Human Research Protection Program guide, section 1.3 Definition of Terms, page 12,
item 106 Human Subject. The data used in this study is deidentified to meet the criteria listed in
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MUSC Human Research Protection Program guide, section 1.3 Definition of Terms, page 7, item
53, part B, containing none of the 18 personal identifiers.
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4) CHAPTER IV RESULTS
The patient sample in this study (n = 2,595,254) was first analyzed following the same
grouping methodology as used by O’Neill Roldan (2018) using the AnyBeers variable to group
patients based on their use of Beers Criteria medications during the study period. This structuring
of the dataset retains the propensity score matching as completed by the original study. Through
this analysis it was determined that the study population for both Beers and non-Beers use was
predominately female and were roughly 74 years of age. Patients in the Beers versus non-Beers
categories were more frail (0.451 vs. 0.353, p < 0.0001), had a higher mean Charlson score (0.09
vs. 0.07, p < 0.0001), and had a significantly larger number of delirium (43,117 vs. 25,727, p <
0.0001) and falls (32,725 vs. 26,255, p < 0.0001) admissions than the non-beers group. It was
determined there was a statistically significant difference in total treatment cost between the two
groups as well. Patients in the Beers group had a total mean treatment cost of almost $15,000,
which is roughly $6,400 dollars more than the non-Beers group ($14,987 vs. 8,580, p < 0.0001).
Patients exposed to Beers medications also experienced a significantly larger number of
hospitalizations for any reason as compared to the non-Beers patients (213,106 vs. 130,489, p <
0.001). Additionally, when comparing the average length of stay between the Beers and nonBeers patients, it was determined that the additional one-half day difference in length of stay was
significant between the Beers and non-Beers patients (6.63 vs. 6.11, p < 0.0001).
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Table 6
Descriptive statistics for all patients by Beers Criteria medication status

Characteristic
Age, years
Hospital Admissions/person
Patients with Any Hospital Admission
Charlson Score
Length of Stay, days
Delirium Admissions
Falls Admissions
Female
Frailty Category
Frailty Cat 0 (Robust)
Frailty Cat 1 (Pre-frail)
Frailty Cat 2 (Frail)
Frailty Score
Insured Days (Member Days)
Geographical Region
Region 1 (Northeast)
Region 2 (North Central)
Region 3 (South)
Region 4 (West)
Region 5 (Unknown)
Total Treatment Cost
Inpatient Cost
Outpatient Cost
Pharmacy (Rx) Cost

Patients receiving no
Beers Medications
(n = 1,297,627)
74.06 ± 6.9
1.197 ± 0.6
130,489 (10.1%)
0.07 ± 0.5
6.11 ± 9.4
25,727 (2.0%)
26,255 (2.0%)
750,416 (57.8%)

Patients receiving ≥1
Beers Medications
(n = 1,297,627)
73.93 ± 6.8
1.263 ± 0.7
213,106 (16.4%)
0.09 ± 0.6
6.63 ± 9.8
43,117 (3.3%)
32,725 (2.5%)
757,171 (58.3%)

949,620 (73.2%)
300,759 (23.2%)
47,248 (3.6%)
0.35 ± 2.2
355 ± 41.8

930,800 (71.7%)
311,359 (24.0)
55,468 (4.3%)
0.45 ± 2.4
355 ± 43.5

293,690 (22.6%)
356,401 (27.5%)
372,216 (28.7%)
263,344 (20.3%)
11,976 (0.9%)
$ 8,580 ± 30,962
$ 2,566 ± 16,055
$ 4,912 ± 23,962
$ 1,102 ± 3,633

291,603 (22.5%)
359,885 (27.7%)
378,048 (29.1%)
257,402 (19.8%)
10,689 (0.8%)
$ 14,987 ± 36,033
$ 4,760 ± 23,238
$ 7,492 ± 21,909
$
2,734 ± 5,590

p-value
<.0001
<.0001
<.0001
<.0001
<.0001
<.0001
<.0001
<.0001
<.0001

<.0001
<.0001
<.0001

<.0001
<.0001
<.0001
<.0001

*Data expressed as mean ± standard deviation (SD) or otherwise indicated as Number (%), and compared by t-test or by MannWhitney U-test.

4.1

Falls and Fractures
When considering the patient population (n = 2,595,254) in regards to falls and fractures

admissions, the analysis determined between the falls patients (n = 58,980) and non-falls patients
(n = 2,536,274) had a larger gap in age (77.52 vs. 73.91, p < 0.0001) and both groups again
being predominately female (65.8% vs. 57.9%, p < 0.0001). The patients who experienced a
fall/fracture admission, similarly to the Beers exposure grouping discussed in the last section, the
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falls patients had a significantly higher Charlson score (0.19 vs. 0.08, p < 0.0001) and frailty
score (1.78 vs. 0.37, p < 0.0001) as compared to patients without a fall or fracture admission.
The falls patients in the study population also experienced a significantly longer average length
of stay (7.84 vs. 6.32, p < 0.0001) and a significantly higher mean number of hospital admissions
per person (1.354 vs. 1.23, p < 0.0001). Interestingly, patients without falls admissions, 49.9% of
these patients were taking at least one Beers Criteria medication. Geographically the analysis
determined the majority of the falls and fractures patients were located in the North Central
region while the majority of non-falls patients were located in the South region. Lastly, there is a
$15,820 dollar difference in total treatment cost between the patients with falls admissions and
those without ($27,244 vs. $11,424, p < 0.0001).
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Table 7
Descriptive statistics for all patients by falls admission

Characteristic
Age, years
Hospital Admissions/person
Patients with Any Hospital Admission
Patients taking Any Beers Medications
Falls Admissions/person
Fall Drug Days
Charlson Score
Length of Stay, days
Female
Frailty Category
Frailty Cat 0 (Robust)
Frailty Cat 1 (Pre-frail)
Frailty Cat 2 (Frail)
Frailty Score
Insured Days (Member Days)
Geographical Region
Region 1 (Northeast)
Region 2 (North Central)
Region 3 (South)
Region 4 (West)
Region 5 (Unknown)
Total Treatment Cost
Inpatient Cost
Outpatient Cost
Pharmacy (Rx) Cost

Patients with no falls
admissions
(n = 2,536,274)
73.91 ± 6.8
1.23 ± 0.6
318,748 (12.3%)
1,264,902 (49.9%)
--0.86 ± 21.7
0.08 ± 0.6
6.32 ± 9.6
1,468,759 (57.9%)

Patients with falls
admissions
(n = 58,980)
77.52 ± 7.1
1.354 ± 0.8
24,847 (1.0%)
32,725 (55.5%)
2.6 ± 3.5
2.82 ± 37.7
0.19 ± 0.8
7.84 ± 10.7
38,828 (65.8%)

1,851,882 (73.0%)
590,096 (23.3%)
94,296 (3.7%)
0.37 ± 2.3
355 ± 42.8

28,538 (48.4%)
22,022 (37.5%)
8,420 (14.3%)
1.78 ± 3.5
357 ± 33.3

572,041 (22.6%)
697,119 (27.5%)
736,512 (29.1%)
508,093 (20.0%)
22,149 (0.9%)
$ 11,424 ± 33,350
$ 3,499 ± 19,677
$ 6,018 ± 22,897
$ 1,907 ± 4,705

12,892 (21.9%)
19,167 (32.5%)
13,752 (23.3%)
12,653 (21.4%)
516 (0.9%)
$ 27,244 ± 45,144
$ 10,742 ± 30,069
$ 14,115 ± 25,644
$
2,387 ± 7,420

p-value
<.0001
<.0001
<.0001
<.0001
<.001
<.0001
<.0001
<.0001
<.0001

<.0001
<.0001
<.0001

<.0001
<.0001
<.0001
<.0001

*Data expressed as mean ± standard deviation (SD) or otherwise indicated as Number (%), and compared by t-test or by MannWhitney U-test.

4.1.1 Medication Class Frequency Analysis
Utilizing the Beers Criteria medication classes selected as ones causing disruptions in
balance and gait which could lead to an injurious fall, a frequency analysis on the prevalence of
each medication class by falls and non-falls patients was performed. For the purposes of this
portion of the analysis, the Beers Criteria medication classes selected were: antipsychotics,
barbiturates, benzodiazepines, sedatives, and tricyclic antidepressants. It was determined that in
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the study population the most commonly used medication class in patients with falls admissions
were benzodiazepines (n = 10,598), followed by antipsychotics, sedatives, tricyclic
antidepressants, and lastly barbiturates (n = 4,008; 2,040; 898; and 231 patients respectively).
For the non-falls patients, it was determined the most frequently used medication class was also
benzodiazepines (n = 354,080), but was followed by sedatives (n = 94,429), not antipsychotics as
with the falls patients. Following sedative use with the non-falls patients were antipsychotics,
tricyclic antidepressants, and lastly barbiturates (n = 58,753; 33,999; and 9,878 patients
respectively). A lower overall percentage of falls patients were found to be taking a medication
in any other Beers Criteria medication class or no Beers medications at all as compared to the
non-falls patients (Other Beers: 25.4% vs. 28.2%; No Beers: 44.5% vs. 50.1%, p < 0.0001).
Table 8
Incidence of falls admissions by Beers Medications categories

Beers Criteria Grouping
Antipsychoticsa
Barbiturates
Benzodiazepinesb
Sedativesc
TCAd
Other Medication Classese
No Beers Medications Present

Patients with no fall
admissions
(n = 2,536,274)

Patients with ≥1 fall
admission
(n = 58,980)

58,753 (2.3%)
9,878 (0.4%)
354,080 (14.0%)
94,429 (3.6%)
33,999 (1.3%)
715,763 (28.2%)
1,271,372 (50.1%)

4,008 (6.8%)
231 (0.4%)
10,598 (18.0%)
2,040 (3.5%)
898 (1.5%)
14,950 (25.4%)
26,255 (44.5%)

p-value
<.0001

a Includes first- and second-generation antipsychotics
b Includes short- and long-acting benzodiazepines
c Includes Nonbarbiturate and nonbenzodiazepine sedatives hypnotics
d Includes tertiary tricyclic antidepressants
e Includes any other classification of Beers Criteria medications

4.1.2 Logistic Regression Results
A logistic regression analysis was performed to determine if there is an increase in risk of
hospitalization from falls between patients taking each of the specified Beers potential fall risk
medication classes listed in section 4.1.1 compared to those taking no Beers medications. The
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five medication classes, along with an “Other Beers Medication” categorical variable was
compared against a baseline of the “No Beers Medications” category. The analysis determined
antipsychotics posed the highest risk of an injurious fall or fracture by 1.93 times (95% CI:
1.865, 2.007), benzodiazepines increased hospitalization due to fall risk by 1.37 times (95% CI:
1.341, 1.405), tricyclic antidepressants by 1.34 times (95% CI: 1.245, 1.427), and lastly,
barbiturates increased this risk by 1.3 times (95% CI: 1.13, 1.472). Sedatives only increased the
risk of hospitalization by 1.18 times (95% CI: 1.13, 1.427) while patients taking any other
medications present on the Beers Criteria were found to have only a very slight risk increase of
1.07 times (95% CI: 1.051, 1.095).
In addition to the specific Beers Criteria medication classes this study analyzed, it is
worth noting other patient characteristics in the final logistic regression model that also had a
significant increase in risk of a fall or fracture admission. One of these characteristics most
notably is the changes in frailty category. Using a robust patient as the baseline (frailcat_0),
patients who moved into the pre-frail category had a 1.8 times (95% CI: 1.777, 1.847) increase in
hospitalization risk while patients who moved into the frail category had a 2.7 times (95% CI:
2.595, 2.778) increase in risk. This study was able to control for a significant number of
Elixhauser Comorbidity and frailty indicators and through these additional controlling variables,
the regression analysis found patients diagnosed with Cystic Fibrosis had a 2.43 times (95% CI:
1.175, 5.06) increase in risk of hospitalization and patients with Multiple Sclerosis were at a 2.0
times increase in risk (95% CI: 1.766, 2.283).
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Table 9
Logistic regression results for falls
Variable
Intercept
BeersCat - APsyco vs No Beers
BeersCat - Barbit vs No Beers
BeersCat - Benzos vs No Beers
BeersCat - OtherRx vs No Beers
BeersCat - Sedativ vs No Beers
BeersCat - TCA vs No Beers
AGE
MEMDAYS
Male
Region_2
Region_3
Region_4
Region_5
HospitalAdm
CharlsScore
FrailCat_1
FrailCat_2
PulmHeart
ConductHeart
CHF
COPD
Asthma
Divert
CRF
RA
SLE
ConductHeartB
Diab
DiabComp
HIV
Hep
CF
Sicle
Senile
Scizo
Parkin

β
-9.6497
0.4089
0.00342
0.0655
-0.1807
-0.0824
0.0364
0.055
0.00381
-0.3325
0.1849
-0.1166
0.1278
0.3346
0.1159
0.00338
0.5944
0.9877
0.1131
0.1853
0.00184
0.1909
0.1631
0.1009
0.2337
0.1367
0.1002
0.0587
0.1544
0.2438
0.2558
0.4527
0.8914
-0.0733
0.2706
-0.0366
0.4776

Odds Ratio
(=eβ)

OR 95% C.I.

1.935
1.290
1.372
1.073
1.184
1.333
1.057
1.004
0.717
1.203
0.89
1.136
1.397
1.123
1.003
1.812
2.685
1.12
1.204
1.002
1.21
1.177
1.106
1.263
1.146
1.105
1.06
1.167
1.276
1.291
1.572
2.438
0.929
1.311
0.964
1.612

[1.865, 2.007]
[1.13, 1.472]
[1.341, 1.405]
[1.051, 1.095]
[1.13, 1.239]
[1.245, 1.427]
[1.055, 1.058]
[1.004, 1.004]
[0.705, 0.73]
[1.176, 1.231]
[0.868, 0.912]
[1.108, 1.165]
[1.277, 1.53]
[1.061, 1.188]
[0.985, 1.023]
[1.777, 1.847]
[2.595, 2.778]
[1.054, 1.19]
[1.136, 1.275]
[0.969, 1.036]
[1.179, 1.242]
[1.13, 1.226]
[1.05, 1.165]
[1.223, 1.305]
[1.086, 1.21]
[0.996, 1.227]
[1, 1.125]
[1.142, 1.193]
[1.241, 1.312]
[0.883, 1.889]
[1.382, 1.789]
[1.175, 5.06]
[0.377, 2.289]
[1.268, 1.355]
[0.812, 1.145]
[1.532, 1.697]

p-value
<.0001
<.0001
0.953
<.0001
<.0001
0.0002
0.2426
<.0001
<.0001
<.0001
<.0001
<.0001
<.0001
<.0001
<.0001
0.7268
<.0001
<.0001
0.0003
<.0001
0.9143
<.0001
<.0001
0.0001
<.0001
<.0001
0.0592
0.0516
<.0001
<.0001
0.1877
<.0001
0.0167
0.8733
<.0001
0.6765
<.0001
(continued)
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Variable
MS
Epil
Otitis
Vertigo
Valve
Carditis
Hyp

β
0.6971
0.533
0.1354
0.3814
0.0374
-0.0437
0.2648

Odds Ratio
(=eβ)
2.008
1.704
1.145
1.464
1.038
0.957
1.303

OR 95% C.I.
[1.766, 2.283]
[1.604, 1.81]
[1.064, 1.233]
[1.409, 1.522]
[1.003, 1.074]
[0.905, 1.012]
[1.28, 1.326]

p-value
<.0001
<.0001
0.0003
<.0001
0.0317
0.1249
<.0001

*c-statistic: 0.725

4.2

Delirium and Confusion
The last patient group this study considered were those with confusion and delirium

admissions. In our entire patient sample (n = 2,595,254), the analysis found differences between
the delirium patients (n = 68,844) and non-delirium patients (n = 2,526,410) in age (78.34 vs.
73.87, p < 0.0001) female sex (58.1% vs. 56.8%, p < 0.0001). The patients who experienced a
confusion or delirium admission, similarly to the Beers exposure grouping discussed at the
beginning of this chapter, the delirium patients had a significantly higher Charlson score (0.34
vs. 0.08, p < 0.0001) and frailty score (2.91 vs. 0.33, p < 0.0001) as compared to patients without
a confusion or delirium admission. The delirium patients in the study experienced a significantly
longer average length of stay (9.86 vs. 5.86 days, p < 0.0001) and a significantly higher mean
number of hospital admissions per person (1.44 vs. 1.20, p < 0.0001).
Also similar to the falls and fracture finding, 49.7% of the patients without a delirium
admissions were taking at least one Beers Criteria medication. The delirium patients had the
highest prevalence of any beers medications out of all three groupings with 62.2% of patients
receiving at least one Beers medication. One of the most noticeable differences when comparing
any stratification of study patients analyzed in this study, is the difference in the total treatment
cost. The patients with a delirium admission were found to have a higher unadjusted mean
treatment cost of $45,380 compared to the non-delirium patients having a mean treatment cost of
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only $10,868, a difference of $34,512 (p < 0.0001) over the follow-up period of April –
December 2013. Geographically, the analysis similarly determined the majority of delirium
patients were located in the North Central region while the majority of non-delirium patients
were located in the South.
Table 10
Descriptive statistics for all patients by delirium admission

Characteristic
Age, years
Hospital Admissions/person
Patients with Any Hospital Admission
Patients taking Any Beers Medications
Charlson Score
Length of Stay, days
Female
Frailty Category
Frailty Cat 0 (Robust)
Frailty Cat 1 (Pre-frail)
Frailty Cat 2 (Frail)
Frailty Score
Insured Days (Member Days)
Geographical Region
Region 1 (Northeast)
Region 2 (North Central)
Region 3 (South)
Region 4 (West)
Region 5 (Unknown)
Total Treatment Cost
Inpatient Cost
Outpatient Cost
Pharmacy (Rx) Cost

Patients with no
delirium admissions
(n = 2,526,410)
73.87 ± 6.8
1.20 ± 0.57
294,398 (11.6%)
1,254,510 (49.7%)
0.08 ± 0.5
5.86 ± 8.5
1,468,454 (58.1%)

Patients with delirium
admissions (n =
68,844)
78.34 ± 6.9
1.44 ± 0.93
49,197 (71.5%)
43,117 (62.6%)
0.34 ± 1.1
9.86 ± 14.4
39,133 (56.8%)

1,853,562 (73.4%)
585,931 (23.2%)
86,917 (3.4%)
0.33 ± 2.2
355 ± 42.3

26,858 (39.0%)
26,187 (38.0%)
15,799 (22.9%)
2.91 ± 4.3
344 ± 52.3

569,998 (22.6%)
693,772 (27.5%)
730,201 (28.9%)
510,282 (20.2%)
22,157 (0.9%)
$ 10,868 ± 31,546
$ 3,154 ± 17,903
$ 5,819 ± 22,347
$ 1,894 ± 4,754

15,295 (22.2%)
22,514 (32.7%)
20,063 (29.1%)
10,464 (15.2%)
508 (0.7%)
$ 45,380 ± 72,459
$ 22,342 ± 54,417
$ 20,240 ± 37,459
$ 2,798 ± 5,735

p-value
<.0001
<.0001
<.0001
<.0001
<.0001
<.0001
<.0001
<.0001

<.0001
<.0001
<.0001

<.0001
<.0001
<.0001
<.0001

*Data expressed as mean ± standard deviation (SD) or otherwise indicated as Number (%), and compared by t-test or by MannWhitney U-test.

4.2.1 Medication Class Frequency Analysis
When considering Beers Criteria medication classes that cause disruptions in cognition
and decreases in cognitive ability, a frequency analysis was again performed for each medication
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class by delirium and the non-delirium patients. For the purposes of this portion of the analysis,
the Beers Criteria medication classes selected for analysis were: antihistamines, antipsychotics,
benzodiazepines, and narcotics. Through this frequency analysis it was determined the most
commonly used medication class in patients with delirium admissions were benzodiazepines (n =
13,308), followed by antipsychotics, antihistamines, and lastly narcotics (n = 10,574; 1,237; and
27 respectively). The non-delirium patients followed the same distribution frequency as the
delirium patients (n = 351,640; 52,187; 49,907; and 1,514 respectively) A lower overall
percentage of delirium patients were found to be taking a medication in any other Beers Criteria
medication class or no Beers medications at all as compared to the non-delirium patients (Other
Beers: 26.5% vs. 31.8%; No Beers: 37.4% vs. 50.3%, p < 0.0001).
Table 11
Incidence of delirium admissions by Beers Medications categories

Characteristic
Beers Criteria Grouping
Antihistamines
Antipsychoticsa
Benzodiazepinesb
Narcotics
Other Medication Classesc
No Beers Medications Present

Patients with no
delirium admissions
(n=2,526,410)

Patients with ≥1
delirium admission
(n=68,844)

45,907 (1.8%)
52,187 (2.1%)
351,640 (13.9%)
1,514 (0.1%)
803,262 (31.8%)
1,271,900 (50.3%)

1,231 (1.8%)
10,574 (15.4%)
13,038 (18.9%)
27 (0.04%)
18,247 (26.5%)
25,727 (37.4%)

p-value
<.0001

a Includes first- and second-generation antipsychotics
b Includes short- and long-acting benzodiazepines
c Includes any other classification of Beers Criteria medications

4.2.2 Logistic Regression Results
Ensuring statistical consistency, the same logistic regression analysis was performed on
the delirium and non-delirium patients to determine the increase in risk of hospitalization when
taking one of the specified confusion and delirium Beers medication classes listed in section
4.2.1. The four medication classes, and the “Other Beers Medication” categorical variable was
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compared against the “No Beers Medications” baseline category. The analysis determined
antipsychotics posed the highest risk for a confusion or delirium admission with 5.12 times
increase in risk (95% CI: 4.985, 4.263), benzodiazepines with 1.8 times increase (95% CI: 1.762,
1.841), and antihistamines increased risk by 1.42 times (95% CI: 1.335, 1.503). Narcotics only
marginally increased the risk of hospitalization by 1.05 times (95% CI: 0.714, 1.544) while
patients taking any other medications present on the Beers Criteria were found to have risk
increase of 1.22 times (95% CI: 1.197, 1.245).
Like the falls and fracture regression analysis, one of the patient characteristics outside of
Beers Criteria medication use found to increase the risk of a confusion or delirium admission
was again frailty category. Using a robust patient as the baseline (frailcat_0), patients who
moved into the pre-frail category had 2.1 times (95% CI: 1.974, 2.051) increase in
hospitalization risk while patients in the frail category had 3.7 times (95% CI: 3.592, 3.809)
increase in risk in hospitalization. As performed in the falls and fracture regression, the
Elixhauser Comorbidity and frailty indicators were included as additional controlling variables.
The regression analysis found patients diagnosed with Sickle Cell Anemia had 2.7 times increase
(95% CI: 1.564, 4.732) in risk of hospitalization and patients with Multiple Sclerosis or Epilepsy
both saw 2.4 times increase (95% CI: 2.126, 2.693; 95% CI: 2.33, 2.57) in risk.
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Table 12
Logistic regression results for delirium
Variable
Intercept
DillBeersCat2 - AHist vs No Beers
DillBeersCat2 - APsyco vs No Beers
DillBeersCat2 - Benzos vs No Beers
DillBeersCat2 - Narcoti vs No Beers
DillBeersCat2 - OtherRx vs No Beers
AGE
MEMDAYS
Male
Region_2
Region_3
Region_4
Region_5
HospitalAdm
CharlsScore
FrailCat_1
FrailCat_2
PulmHeart
ConductHeart
CHF
COPD
Asthma
Divert
CRF
RA
SLE
ConductHeartB
Diab
DiabComp
HIV
Hep
CF
Sicle
Senile
Scizo
Parkin
MS

β
-8.954
-0.1218
1.1638
0.1186
-0.4206
-0.2703
0.0646
-0.00038
0.0685
0.1771
0.1179
-0.226
0.2264
0.3492
0.0354
0.6992
1.3081
0.0524
0.1353
0.0648
0.1806
-0.0608
-0.0163
0.3868
0.024
-0.0481
0.0241
0.2471
0.3605
0.2242
0.5379
-0.6296
1.0008
0.547
0.1281
0.3221
0.8725

Odds Ratio
(=eβ)

OR 95% C.I.

1.416
5.122
1.801
1.05
1.221
1.067
1
1.071
1.194
1.125
0.798
1.254
1.418
1.036
2.012
3.699
1.054
1.145
1.067
1.198
0.941
0.984
1.472
1.024
0.953
1.024
1.28
1.434
1.251
1.712
0.533
2.721
1.728
1.137
1.38
2.393

[1.335, 1.503]
[4.985, 5.263]
[1.762, 1.841]
[0.714, 1.544]
[1.197, 1.245]
[1.065, 1.068]
[0.999, 1]
[1.054, 1.088]
[1.168, 1.22]
[1.1, 1.15]
[0.777, 0.819]
[1.143, 1.375]
[1.357, 1.481]
[1.022, 1.05]
[1.974, 2.051]
[3.592, 3.809]
[0.996, 1.115]
[1.086, 1.207]
[1.037, 1.098]
[1.17, 1.227]
[0.902, 0.982]
[0.934, 1.037]
[1.431, 1.514]
[0.969, 1.082]
[0.852, 1.067]
[0.97, 1.082]
[1.255, 1.307]
[1.399, 1.47]
[0.887, 1.765]
[1.524, 1.925]
[0.161, 1.759]
[1.564, 4.732]
[1.682, 1.775]
[1.006, 1.284]
[1.319, 1.444]
[2.126, 2.693]

p-value
<.0001
0.003
<.0001
0.0005
0.0103
<.0001
<.0001
<.0001
<.0001
<.0001
<.0001
<.0001
<.0001
<.0001
<.0001
<.0001
<.0001
0.068
<.0001
<.0001
<.0001
0.0053
0.5421
<.0001
0.3947
0.402
0.384
<.0001
<.0001
0.2011
<.0001
0.3015
0.0004
<.0001
0.0396
<.0001
<.0001
(continued)
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Variable
Epil
Otitis
Vertigo
Valve
Carditis
Hyp

β
0.8949
-0.0397
0.3154
-0.00934
-0.0461
0.1125

Odds Ratio
(=eβ)
2.447
0.961
1.371
0.991
0.955
1.119

OR 95% C.I.
[2.33, 2.57]
[0.889, 1.04]
[1.319, 1.424]
[0.959, 1.023]
[0.909, 1.003]
[1.1, 1.138]

p-value
<.0001
0.3221
<.0001
0.574
0.0659
<.0001

* c-statistic = 0.80

4.3

Gamma Log-Linked Regression for Study Cost
The final component of this study was the effect of the different Beers Criteria

medication classes on the overall study or treatment cost. Using a gamma log-linked regression,
we found that all 7 medication classes, including the “OtherRx” category, all significantly
increased the total study or treatment costs from the non-Beers exposed control group over a
follow-up period of April – December 2013. As shown in Table 13, the largest effect on study
cost was patients using antipsychotics at $17,692 (95% CI: 17,500, 17,886) followed by narcotic
use at $16,393 (95% CI: 15,201, 17,679). It is worth noting the results for the barbiturates and
tricyclic antidepressant categories are specific for the falls and fracture admissions while the
narcotic category is specific for the confusion and delirium admissions.
Table 13
Gamma log-link regression results for overall study cost
Variable
AHist
APsyco
Barbit
Benzos
Narcoti
Sedativ
TCA

Label
Antihistamines
Antipsychotics
Barbiturates
Benzodiazepines
Narcotics
Sedatives
Tricyclic
Antidepressants
OtherRx Other Beers Rx
zNo_Bee No Beers Rx

β Est.
9.4961
9.7809
9.467
9.6666
9.7046
9.5438

β 95% C.I.
[9.4828, 9.5094]
[9.7699, 9.7918]
[9.4402, 9.4937]
[9.6621, 9.6711]
[9.6291, 9.7801]
[9.535, 9.5525]

9.4485 [9.4341, 9.463]
9.3696 [9.3663, 9.3728]
8.8971 [8.8947, 8.8995]

Exponentiated
(=eβ)
$13,308
$17,692
$12,926
$15,782
$16,393
$13,957
$12,690
$11,726
$ 7,311

eβ 95% C.I.
[13132, 13487]
[17500, 17886]
[12584, 13276]
[15712, 15853]
[15201, 17679]
[13836, 14080]

pvalue
<.0001
<.0001
<.0001
<.0001
<.0001
<.0001
<.0001

[12508, 12874]
[11688, 11765] <.0001
[7293, 7328] <.0001
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Figure 5: Least Squares Means for all Beers Criteria medication classes, overall study cost

When the same gamma log-linked regression model was run specifically on the pharmacy
Rx cost variable similar to the overall study cost model, we found that antipsychotic use was the
largest contributing factor to the change in direct pharmacy costs by $3,858 (95% CI = 3,806,
3,911). Following antipsychotics, benzodiazepines, barbiturates, narcotics, and tricyclic
antidepressants all very similarly contributed to the overall change in pharmacy costs.
Table 14
Gamma log-link regression results for pharmacy Rx cost
Variable
AHist
APsyco
Barbit
Benzos
Narcoti
Sedativ

Label
Antihistamines
Antipsychotics
Barbiturates
Benzodiazepines
Narcotics
Sedatives
Tricyclic
TCA
Antidepressants
OtherRx Other Beers Rx
zNo_Bee No Beers Rx

β Est.
7.8643
8.2579
7.9361
7.9377
7.9294
7.9225

β 95% C.I.
[7.8478, 7.8807]
[8.2443, 8.2715]
[7.9031, 7.9691]
[7.9322, 7.9432]
[7.8364, 8.0224]
[7.9117, 7.9333]

7.9306 [7.9128, 7.9483]
7.6901 [7.6860, 7.6941]
6.8869 [6.8840, 6.8899]

Exponentiated
(=eβ)
$2,602
$3,858
$2,796
$2,801
$2,778
$2,759

eβ 95% C.I.
[2560, 2655]
[3806, 3911]
[2706, 298]
[2785, 2816]
[2531, 3048]
[2729, 2789]

p- value
<.0001
<.0001
<.0001
<.0001
<.0001
<.0001

$2,781
$2,186
$ 979

[2732, 2831]
[2178, 2195]
[977, 982]

<.0001
<.0001
<.0001
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Figure 6: Least Squares Means for all Beers Criteria medication classes, Rx payment costs

The gamma log-linked regression results when considering the effect of the Beers
Criteria medication classes on the outpatient costs yielded a different result than the previous two
models. In this model, the highest contributing factor to outpatient costs was the presence of
narcotics with an average annual outpatient cost of $9,068 (95% CI: 8,631, 9,835). Following
narcotic use, the second largest contributor to outpatient costs were benzodiazepines, followed
by antipsychotics, tricyclic antidepressants, antihistamines, barbiturates, and lastly, sedatives.
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Table 15
Gamma log-link regression results for outpatient costs
Variable
AHist
APsyco
Barbit
Benzos
Narcoti
Sedativ

Label
Antihistamines
Antipsychotics
Barbiturates
Benzodiazepines
Narcotics
Sedatives
Tricyclic
TCA
Antidepressants
OtherRx Other Beers Rx
zNo_Bee No Beers Rx

β Est.
8.7968
8.9174
8.7369
8.9877
9.1125
8.8327

β 95% C.I.
[8.7825, 8.8111]
[8.9056, 8.9292]
[8.7081, 8.7657]
[8.9829, 8.9925]
[9.0313, 9.1937]
[8.7052, 8.7362]

8.7207 [8.6518, 8.6588]
8.6553 [8.8233, 8.8422]
8.3194 [8.3168, 8.3219]

Exponentiated
(=eβ)
$6,613
$7,461
$6,228
$8,004
$9,068
$6,855

eβ 95% C.I.
[6519, 6708]
[7373, 7549]
[6052, 6410]
[7966, 8043]
[8631, 9835]
[6034, 6224]

p- value
<.0001
<.0001
<.0001
<.0001
<.0001
<.0001

$6,129
$5,741
$4,102

[5721, 5761]
[6791, 6920]
[4092, 4113]

<.0001
<.0001
<.0001

Figure 7: Least Squares Means for all Beers Criteria medication classes, outpatient costs

The last gamma log-linked regression analysis performed examined the effect of the
Beers Criteria categories on the inpatient costs. In this model, the antipsychotic medication class
had the largest inpatient costs at $6,240 (95% CI: 6098, 6385). The inpatient model followed the
generalized model and the pharmacy Rx costs model with benzodiazepines having the second
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largest effect. Narcotics, sedatives, antihistamines, barbiturates, and tricyclic antidepressants
followed benzodiazepines in order from next largest effect to smallest.
Table 16
Gamma log-linked regression results for inpatient costs
Variable
AHist
APsyco
Barbit
Benzos
Narcoti
Sedativ

Label
Antihistamines
Antipsychotics
Barbiturates
Benzodiazepines
Narcotics
Sedatives
Tricyclic
TCA
Antidepressants
OtherRx Other Beers Rx
zNo_Bee No Beers Rx

β Est.
8.2552
8.7388
8.2155
8.4820
8.4298
8.3208

β 95% C.I.
[8.2271, 8.2834]
[8.7158, 8.7618]
[8.1589, 8.2721]
[8.4725, 8.4914]
[8.2701, 8.5894]
[8.3022, 8.3393]

8.1615 [8.1310, 8.1920]
8.1884 [8.1815, 8.1953]
7.6219 [7.6169, 7.6269]

Exponentiated
(=eβ)
$3,848
$6,240
$3,698
$4,827
$4,581
$4,108

eβ 95% C.I.
[3741, 3958]
[6098, 6385]
[3494, 3913]
[4781, 4873]
[3905, 5375]
[4033, 4185]

p- value
<.0001
<.0001
<.0001
<.0001
<.0001
<.0001

$3,503
$3,599
$2,042

[3398, 3612]
[3574, 3624]
[2032, 2053]

<.0001
<.0001
<.0001

Figure 8: Least Squares Means results for all Beers Criteria medication classes, inpatient
costs
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5) CHAPTER V DISCUSSION
Overall, patients in both experimental groups were older, had a longer length of stay, and
a higher Charlson Score than their well-matched control groups. Antipsychotics and
benzodiazepines were consistently the most frequent prescribed class of Beers Criteria
medications to both groups of patients who experienced a fall or fracture, or delirium or
confusion admission. Antipsychotics and benzodiazepines were also associated with the greatest
increase in risk of admission both the falls and fractures, and the delirium and confusion groups.
Antipsychotics were associated with the highest overall expected cost of admission and
benzodiazepines third, when considering admission type independently. Narcotics, specifically
considered for the delirium patients, was the second highest contributor to the expected cost of
admission. Figure 9 shows all Beers Criteria medication classes analyzed in this study for the
overall treatment costs for all patients. The baseline total treatment costs for the control groups in
the absence of Beers Criteria medications (NoBeers) was $7,311 and is indicated by the red line
in the figure. The increase in total treatment cost is shown in the bar above the red baseline
relative to the magnitude of the increase by the Beers Criteria medication class.
Figure 9: Effect of Beers Criteria medication class on overall treatment cost
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When specifically considering the patients who experiences a fall or fracture admission,
we found benzodiazepines and antipsychotics as the most frequent Beers Criteria classes
involved with these types of admissions. We also saw an increased risk of a falls and fracture
admission of 1.9 times with antipsychotics, and 1.4 times with benzodiazepines.
Patients with delirium or confusion admissions we again saw benzodiazepines and
antipsychotics as the most frequently involved Beers Criteria classes. We saw an increased risk
of a confusion and delirium admission of 5.1 times with antipsychotic use, 1.8 times with the use
of benzodiazepines, and 1.4 times with the use of antihistamines.
These findings show validation of the logical linkage between the use of certain Beers
Criteria medications and their expected hospital admissions.
5.1

Limitations
As with any study there are limitations we encountered, some could be managed while

others could not due to the design of our study. First, as identified by the O’Neill Roldan (2018)
study during the creation of the study design and dataset, the inclusion of only communitydwelling individuals ≥65 years old would exclude those who are institutionalized in nursing
homes, long-term assisted living, or short-term rehabilitation facilities. This exclusion of a large
segment of the elderly population could skew the actual cost burden placed on the patient, payer,
and healthcare system as the costs data excluded costs relating to skilled nursing, long-term,
palliative, or hospice care.
Second, the use of Truven Marketscan® Administrative Claims data contains its own
logical limitations. The Marketscan® database is a convenience, not a randomized, sample.
Because of this, there are analytical cases where the extracted data may contain unintended
biases which can diminish generalizability to larger populations. This was taken into
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consideration in the initial construction of the data source by O’Neill Roldan (2018) and this
effect and limitation is minimized by our population sample size. Additionally, given the
frequencies calculated for Beers Criteria medication use and general population characteristics,
we in this study found that these proportions are in alignment with already existing literature and
are confident generalizations from our data are accurate.
Marketscan® data is aggregated from data sources which are intended for billing and not
specifically research. Therefore, the accuracy in coding of billing data within the dataset, while
unlikely, could be incorrect causing the unintended exclusion of patients from the original
dataset. While the various Marketscan® databases are touted for their high-quality and
comprehensive coding, the potential for this error could equally affect both groups, so the effect
from this limitation is minimized. Lastly, Marketscan® data only captures encounters data for
which a claim was actually captured. This unintended bias, similar to coding errors, may cause
certain comorbidities, procedures, or medications to not be included in the data set and patients
could be unintentionally excluded.
5.2

Future Research
Due to time constraints, there areas of research planned in this study that could not be

completed. First, future researchers should consider examining different popular combinations of
drug classes and their effects on falls, fractures, delirium, and confusion on community-dwelling
individuals. Second, the examination and investigation of the impact of specific medications
versus an entire class on these types of admissions. Lastly, examining risks of falls, fractures,
confusion, and delirium outside of community-dwelling individuals as this study did, for
example, short-term rehab facilities, long-term care, and skilled nursing facilities. This
suggestion for future research was also considered in O’Neill Roldan (2018).
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5.3

Conclusions
Our study found that patients using antipsychotics are at twice the risk for a fall or

fracture hospitalization than their well-matched controls. Second, our study found patients using
antipsychotics are at more than a five times risk for a delirium or delirium-related hospitalization
than their well-matched controls. We saw with all patients that antipsychotics use was associated
with a $10,381 dollar increase in cost and benzodiazepines use was associated with an $8,471
dollar increase over their well-matched non-Beers baselines. We also found specifically with the
delirium patients, narcotic use was associated with a $9,082 dollar increase in treatment costs
over their well-matched non-Beers baseline.
Through our study we found and can confirm that additional hospital admissions are
logically linked to the expected side effects of certain classes of Beers Criteria medications in
regards to falls and fracture admissions for medications effecting balance and gait; and delirium
and confusion admissions for those medications effecting cognition in the elderly. Future
research and investigation into specific medication-level research and medication class
combinations with regards to falls and fractures, and confusion and delirium in the elderly is
warranted.

69
References

Alassaad, A., Melhus, H., Hammarlund-Udenaes, M., Bertilsson, M., Gillespie, U., &
Sundstrom, J. (2015). A tool for prediction of risk of rehospitalisation and mortality in
the hospitalised elderly: secondary analysis of clinical trial data. BMJ Open, 5(2),
e007259. https://doi.org/10.1136/bmjopen-2014-007259
Allali, G., Launay, C. P., Blumen, H. M., Callisaya, M. L., De Cock, A. M., Kressig, R. W.,
Srikanth, V., Steinmetz, J. P., Verghese, J., Beauchet, O., & Biomathics, C. (2017). Falls,
Cognitive Impairment, and Gait Performance: Results From the GOOD Initiative. J Am
Med Dir Assoc, 18(4), 335-340. https://doi.org/10.1016/j.jamda.2016.10.008
Amann, U., Schmedt, N., & Garbe, E. (2012). Prescribing of potentially inappropriate
medications for the elderly: an analysis based on the PRISCUS list. Deutsches Arzteblatt
international, 109(5), 69-75. https://doi.org/10.3238/arztebl.2012.0069
Ambrose, A. F., Cruz, L., & Paul, G. (2015). Falls and Fractures: A systematic approach to
screening and prevention. Maturitas, 82(1), 85-93.
https://doi.org/10.1016/j.maturitas.2015.06.035
American Geriatrics Society Beers Criteria Update Expert Panel. (2012). American Geriatrics
Society updated Beers Criteria for potentially inappropriate medication use in older
adults. Journal of the American Geriatrics Society, 60(4), 616-631.
https://doi.org/10.1111/j.1532-5415.2012.03923.x
American Geriatrics Society Beers Criteria Update Expert Panel. (2015). American Geriatrics
Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in
Older Adults. J Am Geriatr Soc, 63(11), 2227-2246. https://doi.org/10.1111/jgs.13702

70
American Geriatrics Society Beers Criteria® Update Expert Panel. (2019). American Geriatrics
Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use
in Older Adults. Journal of the American Geriatrics Society, 67(4), 674-694.
https://doi.org/10.1111/jgs.15767
Arias, E., & Xu, J. (2019). United States life tables, 2017. National Vital Statistics Reports,
68(7).
Austin, P. C. (2011). An Introduction to Propensity Score Methods for Reducing the Effects of
Confounding in Observational Studies. Multivariate behavioral research, 46(3), 399-424.
https://doi.org/10.1080/00273171.2011.568786
Awad, A., & Hanna, O. (2019). Potentially inappropriate medication use among geriatric patients
in primary care setting: A cross-sectional study using the Beers, STOPP, FORTA and
MAI criteria. PloS One, 14(6), e0218174. https://doi.org/10.1371/journal.pone.0218174
Baldoni, A. d. O., Ayres, L. R., Martinez, E. Z., Dewulf, N. d. L. S., Dos Santos, V., & Pereira,
L. R. L. (2014). Factors associated with potentially inappropriate medications use by the
elderly according to Beers criteria 2003 and 2012. Int J Clin Pharm, 36(2), 316-324.
https://doi.org/10.1007/s11096-013-9880-y
Bauer, J. (2004). HIPAA: a paradigm shift in the politics of healthcare. Journal of healthcare
information management : JHIM, 18(2), 5-6.
Bauer, T. K., Lindenbaum, K., Stroka, M. A., Engel, S., Linder, R., & Verheyen, F. (2012). Fall
risk increasing drugs and injuries of the frail elderly - evidence from administrative data.
Pharmacoepidemiol Drug Saf, 21(12), 1321-1327. https://doi.org/10.1002/pds.3357

71
Berryman, S. N., Jennings, J., Ragsdale, S., Lofton, T., Huff, D. C., & Rooker, J. S. (2012).
Beers criteria for potentially inappropriate medication use in older adults. Medsurg Nurs,
21(3), 129-132; quiz 133. https://www.ncbi.nlm.nih.gov/pubmed/22866431
Bogunovic, O. J., & Greenfield, S. F. (2004). Practical geriatrics: Use of benzodiazepines among
elderly patients. Psychiatr Serv, 55(3), 233-235. https://doi.org/10.1176/appi.ps.55.3.233
Bourgeois, F. T., Shannon, M. W., Valim, C., & Mandl, K. D. (2010). Adverse drug events in the
outpatient setting: an 11-year national analysis. Pharmacoepidemiology and Drug Safety,
19(9), 901-910. https://doi.org/10.1002/pds.1984
Brath, H., Mehta, N., Savage, R. D., Gill, S. S., Wu, W., Bronskill, S. E., Zhu, L., Gurwitz, J. H.,
& Rochon, P. A. (2018). What Is Known About Preventing, Detecting, and Reversing
Prescribing Cascades: A Scoping Review. Journal of the American Geriatrics Society,
66(11), 2079-2085. https://doi.org/https://doi.org/10.1111/jgs.15543
Brown, J., Li, C., Painter, J., Hutchison, L. C., & Martin, B. (2014). PIH1 - Predictive Validity of
Inappropriate Prescribing Criteria for Adverse Drug Events, Hospitalizations, and
Emergency Department Visits: A Time-To-Event Comparison of the Beers and Stopp
Criteria. Value in Health, 17(7), A505.
https://doi.org/https://doi.org/10.1016/j.jval.2014.08.1531
Caetano, S. J., Sonpavde, G., & Pond, G. R. (2018). C-statistic: A brief explanation of its
construction, interpretation and limitations. European Journal of Cancer, 90, 130-132.
https://doi.org/https://doi.org/10.1016/j.ejca.2017.10.027
Chang, C. M., Chen, M. J., Tsai, C. Y., Ho, L. H., Hsieh, H. L., Chau, Y. L., & Liu, C. Y.
(2011). Medical conditions and medications as risk factors of falls in the inpatient older

72
people: a case-control study. International Journal of Geriatric Psychiatry, 26(6), 602607. https://doi.org/10.1002/gps.2569
Chang, C. M., Liu, P. Y., Yang, Y. H., Yang, Y. C., Wu, C. F., & Lu, F. H. (2005). Use of the
Beers criteria to predict adverse drug reactions among first-visit elderly outpatients.
Pharmacotherapy, 25(6), 831-838. https://doi.org/10.1592/phco.2005.25.6.831
Chiatti, C., Bustacchini, S., Furneri, G., Mantovani, L., Cristiani, M., Misuraca, C., & Lattanzio,
F. (2012). The economic burden of inappropriate drug prescribing, lack of adherence and
compliance, adverse drug events in older people: a systematic review. Drug Saf, 35 Suppl
1, 73-87. https://doi.org/10.1007/BF03319105
Chiu, M. H., Lee, H. D., Hwang, H. F., Wang, S. C., & Lin, M. R. (2015). Medication use and
fall-risk assessment for falls in an acute care hospital. Geriatr Gerontol Int, 15(7), 856863. https://doi.org/10.1111/ggi.12359
Corsonello, A., Onder, G., Abbatecola, A. M., Guffanti, E. E., Gareri, P., & Lattanzio, F. (2012).
Explicit criteria for potentially inappropriate medications to reduce the risk of adverse
drug reactions in elderly people: from Beers to STOPP/START criteria. Drug Saf, 35
Suppl 1, 21-28. https://doi.org/10.1007/BF03319100
Cox, J., Thomas-Hawkins, C., Pajarillo, E., DeGennaro, S., Cadmus, E., & Martinez, M. (2015).
Factors associated with falls in hospitalized adult patients. Applied Nursing Research,
28(2), 78-82. https://doi.org/10.1016/j.apnr.2014.12.003
Curtin, D., Gallagher, P. F., & O'Mahony, D. (2019). Explicit criteria as clinical tools to
minimize inappropriate medication use and its consequences. Ther Adv Drug Saf, 10,
2042098619829431. https://doi.org/10.1177/2042098619829431

73
Dagli, R. J., & Sharma, A. (2014). Polypharmacy: a global risk factor for elderly people. J Int
Oral Health, 6(6), i-ii. https://www.ncbi.nlm.nih.gov/pubmed/25628499
de Jong, M. R., Van der Elst, M., & Hartholt, K. A. (2013). Drug-related falls in older patients:
implicated drugs, consequences, and possible prevention strategies. Ther Adv Drug Saf,
4(4), 147-154. https://doi.org/10.1177/2042098613486829
Dhalwani, N. N., Fahami, R., Sathanapally, H., Seidu, S., Davies, M. J., & Khunti, K. (2017).
Association between polypharmacy and falls in older adults: a longitudinal study from
England. BMJ Open, 7(10), e016358. https://doi.org/10.1136/bmjopen-2017-016358
Diamond, I. R., Grant, R. C., Feldman, B. M., Pencharz, P. B., Ling, S. C., Moore, A. M., &
Wales, P. W. (2014). Defining consensus: a systematic review recommends
methodologic criteria for reporting of Delphi studies. J Clin Epidemiol, 67(4), 401-409.
https://doi.org/10.1016/j.jclinepi.2013.12.002
Dionyssiotis, Y. (2012). Analyzing the problem of falls among older people. International
Journal of General Medicine, 5, 805-813. https://doi.org/10.2147/IJGM.S32651
Dovjak, P. (2012). Tools in polypharmacy. Zeitschrift für Gerontologie und Geriatrie, 45(6),
468-472. https://doi.org/10.1007/s00391-012-0362-y
Drenth-van Maanen, A. C., van Marum, R. J., Knol, W., van der Linden, C. M. J., & Jansen, P.
A. F. (2009). Prescribing Optimization Method for Improving Prescribing in Elderly
Patients Receiving Polypharmacy. Drugs & Aging, 26(8), 687-701.
https://doi.org/10.2165/11316400-000000000-00000
Endsley, S. (2018). Deprescribing Unnecessary Medications: A Four-Part Process. Fam Pract
Manag, 25(3), 28-32. https://www.ncbi.nlm.nih.gov/pubmed/29989773
https://www.aafp.org/fpm/2018/0500/p28.pdf (Family practice management)

74
French, D. D., Campbell, R., Spehar, A., Cunningham, F., Bulat, T., & Luther, S. L. (2006).
Drugs and falls in community-dwelling older people: a national veterans study. Clinical
Therapeutics, 28(4), 619-630. https://doi.org/10.1016/j.clinthera.2006.04.011
Fulton, M., & Allen, E. R. (2005). Polypharmacy in the Elderly: A Literature Review. Journal of
the American Academy of Nurse Practitioners, 17(4), 123-132.
https://doi.org/10.1111/j.1041-2972.2005.0020.x
Gallagher, P., & O’Mahony, D. (2008). STOPP (Screening Tool of Older Persons’ potentially
inappropriate Prescriptions): application to acutely ill elderly patients and comparison
with Beers’ criteria. Age and Ageing, 37(6), 673-679.
https://doi.org/10.1093/ageing/afn197
Gallagher, P. F., Barry, P. J., Ryan, C., Hartigan, I., & O'Mahony, D. (2008). Inappropriate
prescribing in an acutely ill population of elderly patients as determined by Beers'
Criteria. Age Ageing, 37(1), 96-101. https://doi.org/10.1093/ageing/afm116
Gant, T., & Crowland, K. (2017). A Practical Guide to Getting Started with Propensity Scores.
https://support.sas.com/resources/papers/proceedings17/0689-2017.pdf
Garfinkel, D. (2017). Poly-de-prescribing to treat polypharmacy: efficacy and safety.
Therapeutic Advances in Drug Safety, 9(1), 25-43.
https://doi.org/10.1177/2042098617736192
Garfinkel, D., & Mangin, D. (2010). Feasibility Study of a Systematic Approach for
Discontinuation of Multiple Medications in Older Adults: Addressing Polypharmacy.
Archives of Internal Medicine, 170(18), 1648-1654.
https://doi.org/10.1001/archinternmed.2010.355

75
Gelbard, R., Inaba, K., Okoye, O. T., Morrell, M., Saadi, Z., Lam, L., Talving, P., &
Demetriades, D. (2014). Falls in the elderly: a modern look at an old problem. The
American Journal of Surgery, 208(2), 249-253.
https://doi.org/https://doi.org/10.1016/j.amjsurg.2013.12.034
Gelbard, R., Inaba, K., Okoye, O. T., Morrell, M., Saadi, Z., Lam, L., Talving, P., &
Demetriades, D. (2014). Falls in the elderly: a modern look at an old problem. American
Journal of Surgery, 208(2), 249-253. https://doi.org/10.1016/j.amjsurg.2013.12.034
Gokce Kutsal, Y., Barak, A., Atalay, A., Baydar, T., Kucukoglu, S., Tuncer, T., Hizmetli, S.,
Dursun, N., Eyigor, S., Saridogan, M., Bodur, H., Canturk, F., Turhanoglu, A., Arslan, S.,
& Basaran, A. (2009). Polypharmacy in the elderly: a multicenter study. J Am Med Dir
Assoc, 10(7), 486-490. https://doi.org/10.1016/j.jamda.2009.03.018
Hamilton, H., Gallagher, P., Ryan, C., Byrne, S., & O'Mahony, D. (2011). Potentially
inappropriate medications defined by STOPP criteria and the risk of adverse drug events
in older hospitalized patients. Arch Intern Med, 171(11), 1013-1019.
https://doi.org/10.1001/archinternmed.2011.215 (Archives of internal medicine)
Hammond, T., & Wilson, A. (2013). Polypharmacy and falls in the elderly: a literature review.
Nurs Midwifery Stud, 2(2), 171-175. https://doi.org/10.5812/nms.10709
Haque, R. (2009). ARMOR: a tool to evaluate polypharmacy in elderly persons. Annals of LongTerm Care, 17(6), 26-30.
Haque, R., & Alavi, Z. (2019). Assessing the impact of an interdisciplinary team approach using
the armor protocol on the rate of psychotropic medications and other quality indicators in
long-term care facilities. Annals of Long-Term Care, 27(5), 24-31.
https://doi.org/10.25270/altc.2019.03.00063

76
Hasson, F., Keeney, S., & McKenna, H. (2000). Research guidelines for the Delphi survey
technique. Journal of Advanced Nursing, 32(4), 1008-1015.
https://doi.org/10.1046/j.1365-2648.2000.t01-1-01567.x
Henschel, F., Redaelli, M., Siegel, M., & Stock, S. (2015). Correlation of Incident Potentially
Inappropriate Medication Prescriptions and Hospitalization: An Analysis Based on the
PRISCUS List. Drugs Real World Outcomes, 2(3), 249-259.
https://doi.org/10.1007/s40801-015-0035-4
Hester, A. L., & Wei, F. (2013). Falls in the community: state of the science. Clin Interv Aging,
8, 675-679. https://doi.org/10.2147/CIA.S44996
Hoffman, G. J., Hays, R. D., Shapiro, M. F., Wallace, S. P., & Ettner, S. L. (2016). Claims-based
Identification Methods and the Cost of Fall-related Injuries Among US Older Adults.
Med Care, 54(7), 664-671. https://doi.org/10.1097/MLR.0000000000000531
Hohl, C. M., Dankoff, J., Colacone, A., & Afilalo, M. (2001). Polypharmacy, adverse drugrelated events, and potential adverse drug interactions in elderly patients presenting to an
emergency department. Annals of Emergency Medicine, 38(6), 666-671.
https://doi.org/10.1067/mem.2001.119456
Holt, S., Schmiedl, S., & Thürmann, P. A. (2010). Potentially inappropriate medications in the
elderly: the PRISCUS list. Deutsches Arzteblatt international, 107(31-32), 543-551.
https://doi.org/10.3238/arztebl.2010.0543
Hosseini, S. R., Zabihi, A., Jafarian Amiri, S. R., & Bijani, A. (2018). Polypharmacy among the
Elderly. J Midlife Health, 9(2), 97-103. https://doi.org/10.4103/jmh.JMH_87_17

77
Huang, A. R., Mallet, L., Rochefort, C. M., Eguale, T., Buckeridge, D. L., & Tamblyn, R.
(2012). Medication-Related Falls in the Elderly. Drugs & Aging, 29(5), 359-376.
https://doi.org/10.2165/11599460-000000000-00000
Hudhra, K., Garcia-Caballos, M., Jucja, B., Casado-Fernandez, E., Espigares-Rodriguez, E., &
Bueno-Cavanillas, A. (2014). Frequency of potentially inappropriate prescriptions in
older people at discharge according to Beers and STOPP criteria [Report]. International
Journal of Clinical Pharmacy(3), 596. https://doi.org/10.1007/s11096-014-9943-8
Institute of Medicine. (2000). To Err Is Human: Building a Safer Health System. The National
Academies Press. https://doi.org/doi:10.17226/9728
Jokanovic, N., Tan, E. C., Dooley, M. J., Kirkpatrick, C. M., & Bell, J. S. (2015). Prevalence and
factors associated with polypharmacy in long-term care facilities: a systematic review. J
Am Med Dir Assoc, 16(6), 535 e531-512. https://doi.org/10.1016/j.jamda.2015.03.003
Kalisch Ellett, L. M., Pratt, N. L., Ramsay, E. N., Sluggett, J. K., Barratt, J. D., & Roughead, E.
E. (2016). Central Nervous System-Acting Medicines and Risk of Hospital Admission
for Confusion, Delirium, or Dementia. Journal of the American Medical Directors
Association, 17(6), 530-534. https://doi.org/https://doi.org/10.1016/j.jamda.2016.02.008
Kalisch, L. M., Caughey, G. E., Roughead, E. E., & Gilbert, A. L. (2011). The prescribing
cascade.
Karandikar, Y. S., Chaudhari, S. R., Dalal, N. P., Sharma, M., & Pandit, V. A. (2013).
Inappropriate prescribing in the elderly: A comparison of two validated screening tools.
Journal of Clinical Gerontology and Geriatrics, 4(4), 109-114.
https://doi.org/https://doi.org/10.1016/j.jcgg.2013.04.004

78
Kim, J., & Parish, A. L. (2017). Polypharmacy and medication management in older adults.
Nursing Clinics, 52(3), 457-468.
Kragh, A., Elmståhl, S., & Atroshi, I. (2011). Older adults' medication use 6 months before and
after hip fracture: a population-based cohort study. J Am Geriatr Soc, 59(5), 863-868.
https://doi.org/10.1111/j.1532-5415.2011.03372.x
LaMantia, M. A., Platts-Mills, T. F., Biese, K., Khandelwal, C., Forbach, C., Cairns, C. B.,
Busby-Whitehead, J., & Kizer, J. S. (2010). Predicting hospital admission and returns to
the emergency department for elderly patients. Acad Emerg Med, 17(3), 252-259.
https://doi.org/10.1111/j.1553-2712.2009.00675.x
Louis, D. Z., Robeson, M., McAna, J., Maio, V., Keith, S. W., Liu, M., Gonnella, J. S., & Grilli,
R. (2014). Predicting risk of hospitalisation or death: a retrospective population-based
analysis. BMJ Open, 4(9), e005223. https://doi.org/10.1136/bmjopen-2014-005223
Lund, B. C., Schroeder, M. C., Middendorff, G., & Brooks, J. M. (2015). Effect of
Hospitalization on Inappropriate Prescribing in Elderly Medicare Beneficiaries. Journal
of the American Geriatrics Society, 63(4), 699-707. https://doi.org/10.1111/jgs.13318
Maciejewski, M. L., Diehr, P., Smith, M. A., & Hebert, P. (2002). Common methodological
terms in health services research and their synonyms [correction of symptoms]. Med
Care, 40(6), 477-484. https://doi.org/10.1097/00005650-200206000-00005
Manzano, J.-G. M., Luo, R., Elting, L. S., George, M., & Suarez-Almazor, M. E. (2014). Patterns
and Predictors of Unplanned Hospitalization in a Population-Based Cohort of Elderly
Patients With GI Cancer. Journal of Clinical Oncology, 32(31), 3527-3533.
https://doi.org/10.1200/JCO.2014.55.3131

79
McCarthy, L. M., Visentin, J. D., & Rochon, P. A. (2019). Assessing the Scope and
Appropriateness of Prescribing Cascades. Journal of the American Geriatrics Society,
67(5), 1023-1026. https://doi.org/https://doi.org/10.1111/jgs.15800
McCormick, W. C., Inui, T. S., & Roter, D. L. (1996). Interventions in Physician-Elderly Patient
Interactions. Research on Aging, 18(1), 103-136.
https://doi.org/10.1177/0164027596181007
McMillan, S. S., King, M., & Tully, M. P. (2016). How to use the nominal group and Delphi
techniques. Int J Clin Pharm, 38(3), 655-662. https://doi.org/10.1007/s11096-016-0257-x
Medical University of South Carolina. (2019). Human Research Protection Program Guide,
Section 1.3, Definition of Terms.
https://musc.policytech.com/dotNet/documents/?docid=3770&public=true
Milos, V., Bondesson, A., Magnusson, M., Jakobsson, U., Westerlund, T., & Midlov, P. (2014).
Fall risk-increasing drugs and falls: a cross-sectional study among elderly patients in
primary care. BMC Geriatrics, 14, 40. https://doi.org/10.1186/1471-2318-14-40
Mitchell, K., Mitchell, S. H., Medley, G., Bennett, K. A., Sutton, P. R., Crawford, C. A., Bentov,
I., Damodarasamy, M., Kaplan, S. J., & Reed, M. J. (2017). Older adults and high-risk
medication administration in the emergency department. Drug, Healthcare and Patient
Safety, 9, 105-112. https://doi.org/http://dx.doi.org/10.2147/DHPS.S143341
Mitty, E. (2009). Medication Management in Assisted Living: A National Survey of Policies and
Practices. Journal of the American Medical Directors Association, 10(2), 107-114.
https://doi.org/https://doi.org/10.1016/j.jamda.2008.08.006
Murray, M. D., Morrow, D. G., Weiner, M., Clark, D. O., Tu, W., Deer, M. M., Brater, D. C., &
Weinberger, M. (2004). A conceptual framework to study medication adherence in older

80
adults. Am J Geriatr Pharmacother, 2(1), 36-43. https://doi.org/10.1016/s15435946(04)90005-0
National Center for Health Statistics. (2019). Health, United States, 2018 - Table 038:
Prescription drug use in the past 30 days, by sex, race and Hispanic origin, and age:
United States, selected years 1988–1994 through 2013–2016.
Neutel, C. I., Hirdes, J. P., Maxwell, C. J., & Patten, S. B. (1996). New evidence on
benzodiazepine use and falls: the time factor. Age Ageing, 25(4), 273-278.
https://doi.org/10.1093/ageing/25.4.273
Neutel, C. I., Perry, S., & Maxwell, C. (2002). Medication use and risk of falls.
Pharmacoepidemiol Drug Saf, 11(2), 97-104. https://doi.org/10.1002/pds.686
O'Connell, M. B., Chang, F., Tocco, A., Mills, M. E., Hwang, J. M., Garwood, C. L., Khreizat,
H. S., & Gupta, N. S. (2015). Drug-Related-Problem Outcomes and Program Satisfaction
from a Comprehensive Brown Bag Medication Review
[https://doi.org/10.1111/jgs.13597]. Journal of the American Geriatrics Society, 63(9),
1900-1905. https://doi.org/https://doi.org/10.1111/jgs.13597
O'Mahony, D., O'Sullivan, D., Byrne, S., O'Connor, M. N., Ryan, C., & Gallagher, P. (2015).
STOPP/START criteria for potentially inappropriate prescribing in older people: version
2. Age and ageing, 44(2), 213-218. https://doi.org/10.1093/ageing/afu145
O'Neill Roldan, C. (2018). Effect of Beers criteria on healthcare utilization and costs in
community-dwelling elderly patients Medical University of South Carolina]. Charleston.
http://digital.library.musc.edu/cdm/singleitem/collection/medica/id/1444/rec/1
Oliveira, M. G., Amorim, W. W., de Jesus, S. R., Heine, J. M., Coqueiro, H. L., & Passos, L. C.
S. (2015). A comparison of the Beers and STOPP criteria for identifying the use of

81
potentially inappropriate medications among elderly patients in primary care. Journal of
Evaluation in Clinical Practice, 21(2), 320-325. https://doi.org/10.1111/jep.12319
Olson, C. H., Dierich, M., Adam, T., & Westra, B. L. (2014). Optimization of decision support
tool using medication regimens to assess rehospitalization risks. Appl Clin Inform, 5(3),
773-788. https://doi.org/10.4338/ACI-2014-04-RA-0040
Panneman, M. J., Goettsch, W. G., Kramarz, P., & Herings, R. M. (2003). The costs of
benzodiazepine-associated hospital-treated fall Injuries in the EU: a Pharmo study. Drugs
Aging, 20(11), 833-839. https://doi.org/10.2165/00002512-200320110-00004
Parameswaran Nair, N., Chalmers, L., Connolly, M., Bereznicki, B. J., Peterson, G. M., Curtain,
C., Castelino, R. L., & Bereznicki, L. R. (2016). Prediction of Hospitalization due to
Adverse Drug Reactions in Elderly Community-Dwelling Patients (The PADR-EC
Score). PloS One, 11(10), e0165757. https://doi.org/10.1371/journal.pone.0165757
Parameswaran Nair, N., Chalmers, L., Peterson, G. M., Bereznicki, B. J., Castelino, R. L., &
Bereznicki, L. R. (2016). Hospitalization in older patients due to adverse drug reactions the need for a prediction tool. Clin Interv Aging, 11, 497-505.
https://doi.org/10.2147/CIA.S99097
Parekh, N., Ali, K., Davies, J. G., & Rajkumar, C. (2019). Do the 2015 Beers Criteria predict
medication‐related harm in older adults? Analysis from a multicentre prospective study in
the United Kingdom. Pharmacoepidemiology and drug safety, 28(11), 1464-1469.
https://doi.org/10.1002/pds.4849
Pariente, A., Dartigues, J. F., Benichou, J., Letenneur, L., Moore, N., & Fourrier-Reglat, A.
(2008). Benzodiazepines and injurious falls in community dwelling elders. Drugs Aging,
25(1), 61-70. https://doi.org/10.2165/00002512-200825010-00007

82
Piggott, K. L., Mehta, N., Wong, C. L., & Rochon, P. A. (2020). Using a clinical process map to
identify prescribing cascades in your patient. BMJ, 368, m261.
https://doi.org/10.1136/bmj.m261
Planton, J., & Edlund, B. J. (2010). Strategies for reducing polypharmacy in older adults. Journal
of Gerontological Nursing, 36(1), 8-12. https://doi.org/10.3928/00989134-20091204-03
Powell, C. (2003). The Delphi technique: myths and realities. J Adv Nurs, 41(4), 376-382.
https://doi.org/10.1046/j.1365-2648.2003.02537.x
Price, S. D., Holman, C. D., Sanfilippo, F. M., & Emery, J. D. (2014a). Are high-care nursing
home residents at greater risk of unplanned hospital admission than other elderly patients
when exposed to Beers potentially inappropriate medications? Geriatr Gerontol Int,
14(4), 934-941. https://doi.org/10.1111/ggi.12200
Price, S. D., Holman, C. D., Sanfilippo, F. M., & Emery, J. D. (2014b). Association between
potentially inappropriate medications from the Beers criteria and the risk of unplanned
hospitalization in elderly patients. Ann Pharmacother, 48(1), 6-16.
https://doi.org/10.1177/1060028013504904
Quan, H., Sundararajan, V., Halfon, P., Fong, A., Burnand, B., Luthi, J.-C., Saunders, L. D.,
Beck, C. A., Feasby, T. E., & Ghali, W. A. (2005). Coding Algorithms for Defining
Comorbidities in ICD-9-CM and ICD-10 Administrative Data. Medical Care, 43(11),
1130-1139. https://doi.org/10.1097/01.mlr.0000182534.19832.83
Quinn, K. J., & Shah, N. H. (2017). A dataset quantifying polypharmacy in the United States. Sci
Data, 4, 170167. https://doi.org/10.1038/sdata.2017.167

83
Ray, W. A., Thapa, P. B., & Gideon, P. (2000). Benzodiazepines and the risk of falls in nursing
home residents. J Am Geriatr Soc, 48(6), 682-685. https://doi.org/10.1111/j.15325415.2000.tb04729.x
Rothenberg, K. A., Stern, J. R., George, E. L., Trickey, A. W., Morris, A. M., Hall, D. E.,
Johanning, J. M., Hawn, M. T., & Arya, S. (2019). Association of Frailty and
Postoperative Complications With Unplanned Readmissions After Elective Outpatient
Surgery. JAMA Network Open, 2(5), e194330-e194330.
https://doi.org/10.1001/jamanetworkopen.2019.4330
Sakr, S., Hallit, S., Haddad, M., & Khabbaz, L. R. (2018). Assessment of potentially
inappropriate medications in elderly according to Beers 2015 and STOPP criteria and
their association with treatment satisfaction. Archives of Gerontology and Geriatrics, 78,
132-138. https://doi.org/10.1016/j.archger.2018.06.009
Salgueiro-Vázquez, M. E., Jimeno-Demuth, F. J., & Manso, G. (2016). Beers versus STOPP
criteria in polyharmacy community-dwelling older patients [article]. Farmacia
Hospitalaria, 40(3), 150-164.
https://doaj.org/article/e91b52dbbc0f439aaeaf5831d6a7c832
Sarwar, M. R., Dar, A. R., Mahar, S. Y., Riaz, T., Danish, U., & Iftikhar, S. (2018). Assessment
of prescribing potentially inappropriate medications listed in Beers criteria and its
association with the unplanned hospitalization: a cross-sectional study in Lahore,
Pakistan. Clin Interv Aging, 13, 1485-1495. https://doi.org/10.2147/CIA.S173942
Schwab, C., Hindlet, P., Sabatier, B., Fernandez, C., & Korb-Savoldelli, V. (2019). Risk scores
identifying elderly inpatients at risk of 30-day unplanned readmission and accident and

84
emergency department visit: a systematic review. BMJ Open, 9(7), e028302.
https://doi.org/10.1136/bmjopen-2018-028302
Scott, I. A., Gray, L. C., Martin, J. H., & Mitchell, C. A. (2012). Minimizing Inappropriate
Medications in Older Populations: A 10-step Conceptual Framework. The American
Journal of Medicine, 125(6), 529-537.e524.
https://doi.org/10.1016/j.amjmed.2011.09.021
Scott, I. A., Hilmer, S. N., Reeve, E., Potter, K., Le Couteur, D., Rigby, D., Gnjidic, D., Del Mar,
C. B., Roughead, E. E., Page, A., Jansen, J., & Martin, J. H. (2015). Reducing
Inappropriate Polypharmacy: The Process of Deprescribing. JAMA Internal Medicine,
175(5), 827-834. https://doi.org/10.1001/jamainternmed.2015.0324
Sergi, G., De Rui, M., Sarti, S., & Manzato, E. (2011). Polypharmacy in the elderly: can
comprehensive geriatric assessment reduce inappropriate medication use? Drugs Aging,
28(7), 509-518. https://doi.org/10.2165/11592010-000000000-00000 (Drugs & aging)
Siebert, S., Elkeles, B., Hempel, G., Kruse, J., & Smollich, M. (2013). [The PRISCUS list in
clinical routine. Practicability and comparison to international PIM lists]. Zeitschrift für
Gerontologie und Geriatrie, 46(1), 35-47. https://doi.org/10.1007/s00391-012-0324-4
(Die PRISCUS-Liste im klinischen Test. Praktikabilität und Vergleich mit internationalen
PIM-Listen.)
Simon, G. E., & Ludman, E. J. (2006). Outcome of new benzodiazepine prescriptions to older
adults in primary care. General Hospital Psychiatry, 28(5), 374-378.
https://doi.org/10.1016/j.genhosppsych.2006.05.008
Tandon, P., Tangri, N., Thomas, L., Zenith, L., Shaikh, T., Carbonneau, M., Ma, M., Bailey, R.
J., Jayakumar, S., Burak, K. W., Abraldes, J. G., Brisebois, A., Ferguson, T., &

85
Majumdar, S. R. (2016). A Rapid Bedside Screen to Predict Unplanned Hospitalization
and Death in Outpatients With Cirrhosis: A Prospective Evaluation of the Clinical Frailty
Scale. Official journal of the American College of Gastroenterology | ACG, 111(12).
https://journals.lww.com/ajg/Fulltext/2016/12000/A_Rapid_Bedside_Screen_to_Predict_
Unplanned.22.aspx
Thiruchelvam, K., Hasan, S. S., Wong, P. S., & Kairuz, T. (2017). Residential Aged Care
Medication Review to Improve the Quality of Medication Use: A Systematic Review.
Journal of the American Medical Directors Association, 18(1), 87.e81-87.e14.
https://doi.org/https://doi.org/10.1016/j.jamda.2016.10.004
Tinetti, M. E., Gordon, C., Sogolow, E., Lapin, P., & Bradley, E. H. (2006). Fall-Risk Evaluation
and Management: Challenges in Adopting Geriatric Care Practices. The Gerontologist,
46(6), 717-725. https://doi.org/10.1093/geront/46.6.717
Toronto, C. (2017). Considerations when conducting e-Delphi research: a case study. Nurse Res,
25(1), 10-15. https://doi.org/10.7748/nr.2017.e1498
U.S. Food and Drug Administration. (2019). National Drug Code Directory.
https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory
US Department of Health and Human Services Office of Disease Prevention and Health
Promotion. (2014). National Action Plan for Adverse Drug Event Prevention.
Waters, T. M., Chandler, A. M., Mion, L. C., Daniels, M. J., Kessler, L. A., Miller, S. T., &
Shorr, R. I. (2013). Use of International Classification of Diseases, Ninth Revision,
Clinical Modification, codes to identify inpatient fall-related injuries. J Am Geriatr Soc,
61(12), 2186-2191. https://doi.org/10.1111/jgs.12539

86
Weiner, D. K., Hanlon, J. T., & Studenski, S. A. (1998). Effects of central nervous system
polypharmacy on falls liability in community-dwelling elderly. Gerontology, 44(4), 217221.
Williams, M. E., Pulliam, C. C., Hunter, R., Johnson, T. M., Owens, J. E., Kincaid, J., Porter, C.,
& Koch, G. (2004). The Short-Term Effect of Interdisciplinary Medication Review on
Function and Cost in Ambulatory Elderly People. Journal of the American Geriatrics
Society, 52(1), 93-98. https://doi.org/https://doi.org/10.1111/j.1532-5415.2004.52016.x
Wimmer, B. C., Dent, E., Bell, J. S., Wiese, M. D., Chapman, I., Johnell, K., & Visvanathan, R.
(2014). Medication Regimen Complexity and Unplanned Hospital Readmissions in Older
People. Ann Pharmacother, 48(9), 1120-1128.
https://doi.org/10.1177/1060028014537469
Zia, A., Kamaruzzaman, S. B., & Tan, M. P. (2015). Polypharmacy and falls in older people:
Balancing evidence-based medicine against falls risk. Postgraduate Medicine, 127(3),
330-337. https://doi.org/10.1080/00325481.2014.996112

87
Appendix A: 2012 Beers List Medications
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Source: American Geriatrics Society 2012 Beers Criteria Update Expert Panel (2012). American
Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older
adults. Journal of the American Geriatrics Society, 60(4), 616–631.
https://doi.org/10.1111/j.1532-5415.2012.03923.x
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Appendix B: 2012 Beers Criteria Medications Added and Removed

97

98

Source: American Geriatrics Society 2012 Beers Criteria Update Expert Panel (2012). American
Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older
adults. Journal of the American Geriatrics Society, 60(4), 616–631.
https://doi.org/10.1111/j.1532-5415.2012.03923.x
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Appendix C: 2015 Beers Criteria Medications Added and Removed

Source: By the American Geriatrics Society 2015 Beers Criteria Update Expert Panel (2015).
American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate
Medication Use in Older Adults. Journal of the American Geriatrics Society, 63(11), 2227–2246.
https://doi.org/10.1111/jgs.13702
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Appendix D: 2019 Beers Criteria Medications
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Source: American Geriatrics Society Beers Criteria® Update Expert Panel. (2019). American
Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication
Use in Older Adults. Journal of the American Geriatrics Society, 67(4), 674-694.
https://doi.org/10.1111/jgs.15767
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Appendix E: 2019 Beers Criteria Medications Added and Removed

107

Source: American Geriatrics Society Beers Criteria® Update Expert Panel. (2019). American
Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication
Use in Older Adults. Journal of the American Geriatrics Society, 67(4), 674-694.
https://doi.org/10.1111/jgs.15767

108
Table 17
List of dataset variables for Saber (2020)
Col#
144
147
3
39
159
38
41
160
40
120
43
161
42
45
162
44
47
163
46
49
164
48
51
165
50
53
166
52
55
167
54
57
168
56
59
169
58

Variable
ADMS
adms_0
AGE
Alpha_Agonist_Central_Dys
Alpha_Agonist_Central_IND
Alpha_Agonist_Central_Rx
Alpha_Blocker_Dys
Alpha_Blocker_IND
Alpha_Blocker_Rx
Ambu
Antiarrhythmic_Dys
Antiarrhythmic_IND
Antiarrhythmic_Rx
Antiemetics_Dys
Antiemetics_IND
Antiemetics_Rx
Antihistamine_1st_Gen_Dys
Antihistamine_1st_Gen_IND
Antihistamine_1st_Gen_Rx
Antihypertensive_Dys
Antihypertensive_IND
Antihypertensive_Rx
Antiinfective_Dys
Antiinfective_IND
Antiinfective_Rx
Antiparkinson_agent_Dys
Antiparkinson_agent_IND
Antiparkinson_agent_Rx
Antipsychotics_FirstGen_Dys
Antipsychotics_FirstGen_IND
Antipsychotics_FirstGen_Rx
Antipsychotics_SecondGen_Dys
Antipsychotics_SecondGen_IND
Antipsychotics_SecondGen_Rx
Antispasmodic_Dys
Antispasmodic_IND
Antispasmodic_Rx

Label
# of Hospital Admissions
# of Hospital Admissions
Age of Patient
Beers Criteria Medication Class, Rx Days
Beers Criteria Medication Class, Binary Indicator
Beers Criteria Medication Class, # Rx
Beers Criteria Medication Class, Rx Days
Beers Criteria Medication Class, Binary Indicator
Beers Criteria Medication Class, # Rx
Frailty Measure Indicator
Beers Criteria Medication Class, Rx Days
Beers Criteria Medication Class, Binary Indicator
Beers Criteria Medication Class, # Rx
Beers Criteria Medication Class, Rx Days
Beers Criteria Medication Class, Binary Indicator
Beers Criteria Medication Class, # Rx
Beers Criteria Medication Class, Rx Days
Beers Criteria Medication Class, Binary Indicator
Beers Criteria Medication Class, # Rx
Beers Criteria Medication Class, Rx Days
Beers Criteria Medication Class, Binary Indicator
Beers Criteria Medication Class, # Rx
Beers Criteria Medication Class, Rx Days
Beers Criteria Medication Class, Binary Indicator
Beers Criteria Medication Class, # Rx
Beers Criteria Medication Class, Rx Days
Beers Criteria Medication Class, Binary Indicator
Beers Criteria Medication Class, # Rx
Beers Criteria Medication Class, Rx Days
Beers Criteria Medication Class, Binary Indicator
Beers Criteria Medication Class, # Rx
Beers Criteria Medication Class, Rx Days
Beers Criteria Medication Class, Binary Indicator
Beers Criteria Medication Class, # Rx
Beers Criteria Medication Class, Rx Days
Beers Criteria Medication Class, Binary Indicator
Beers Criteria Medication Class, # Rx
(continued)
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Col#
61
170
60
63
171
62
148
100
113
14
65
172
64
158
67
173
66
69
174
68
101
116
105
32
22
8
12
102
10
11
13
16
143
146
104
18
19
118
109
155

Variable
Antithrombotic_Dys
Antithrombotic_IND
Antithrombotic_Rx
Anxiolytic_Dys
Anxiolytic_IND
Anxiolytic_Rx
AnyADM
AnyBeers
arthritis
Asthma
Barbiturates_Dys
Barbiturates_IND
Barbiturates_Rx
BeersCat
Benzodiazepines_Long_Acting_Dys
Benzodiazepines_Long_Acting_IND
Benzodiazepines_Long_Acting_Rx
Benzodiazepines_Short_Acting_Dys
Benzodiazepines_Short_Acting_IND
Benzodiazepines_Short_Acting_Rx
bladder
braininj
cancer
Carditis
CF
CharlsScore
CHF
coagulopathy
ConductHeart
ConductHeartB
COPD
CRF
Days
days_0
dementia
Diab
DiabComp
diabetes
diffwalk
Dill

Label
Beers Criteria Medication Class, Rx Days
Beers Criteria Medication Class, Binary Indicator
Beers Criteria Medication Class, # Rx
Beers Criteria Medication Class, Rx Days
Beers Criteria Medication Class, Binary Indicator
Beers Criteria Medication Class, # Rx
Any Hospital Admission, Binary Indicator
Any Beers Medication Present, Binary Indicator
Frailty Measure Indicator
Elixhauser Comorbidity Indicator
Beers Criteria Medication Class, Rx Days
Beers Criteria Medication Class, Binary Indicator
Beers Criteria Medication Class, # Rx
Beers Criteria Medication Class, Categorical, Study-based
Beers Criteria Medication Class, Rx Days
Beers Criteria Medication Class, Binary Indicator
Beers Criteria Medication Class, # Rx
Beers Criteria Medication Class, Rx Days
Beers Criteria Medication Class, Binary Indicator
Beers Criteria Medication Class, # Rx
Charlson Comorbidity Score Indicator
Charlson Comorbidity Score Indicator
Charlson Comorbidity Score Indicator
Elixhauser Comorbidity Indicator
Elixhauser Comorbidity Indicator
Charlson Score
Elixhauser Comorbidity Indicator
Charlson Comorbidity Score Indicator
Elixhauser Comorbidity Indicator
Elixhauser Comorbidity Indicator
Elixhauser Comorbidity Indicator
Elixhauser Comorbidity Indicator
Length of Stay, # of Days
Length of Stay, # of Days
Charlson Comorbidity Score Indicator
Elixhauser Comorbidity Indicator
Elixhauser Comorbidity Indicator
Charlson Comorbidity Score Indicator
Frailty Measure Indicator
Delirium Admission, Binary Indicator
(continued)
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Col#
193
194
156
71
175
70
15
5
1
28
73
176
72
153
151
152
150
149
192
195
126
123
134
132
133
122
75
177
74
106
21
119
20
121
77
178
76
124
33
35

Variable
DillBeersCat
DillBeersCat2
DillNum
Diuretic_Dys
Diuretic_IND
Diuretic_Rx
Divert
EGEOLOC
ENROLID
Epil
Ergoloid_Dys
Ergoloid_IND
Ergoloid_Rx
FallDrug
FallDrugDays
FallDrugMos
FallNum
Falls
FallsBeersCat
FallsDillBeersCats
Female
FrailCat
FrailCat_0
FrailCat_1
FrailCat_2
FrailScore
Gut_motility_stimulator_Dys
Gut_motility_stimulator_IND
Gut_motility_stimulator_Rx
heartfail
Hep
HHBed
HIV
HomeO2
Hormones_Dys
Hormones_IND
Hormones_Rx
HospitalAdm
Hyp
LateStroke

Label
Delirium Beers Medication Class, Categorical
Delirium Beers Medication Class, Categorical
# of Hospital Admissions, Delirium Specific
Beers Criteria Medication Class, Rx Days
Beers Criteria Medication Class, Binary Indicator
Beers Criteria Medication Class, # Rx
Elixhauser Comorbidity Indicator
Geographic Location Employee
Enrollee ID
Elixhauser Comorbidity Indicator
Beers Criteria Medication Class, Rx Days
Beers Criteria Medication Class, Binary Indicator
Beers Criteria Medication Class, # Rx
Fall Beers Medication Class, Binary Indicator
# of Rx Days for Combined Fall Drug Medication Classes
# of Rx Mos for Combined Fall Drug Medication Classes
# of Hospital Admissions, Falls Specific
Falls Admission, Binary Indicator
Fall Beers Medication Class, Categorical
Fall and Delirium Beers Medication Classes, Categorical
Gender, Female
Frailty Category, Categorical
Frailty Indicator, Pre-Frail, Binary Indicator
Frailty Indicator, Frail, Binary Indicator
Frailty Indicator, Robust, Binary Indicator
Calculated Frailty Score
Beers Criteria Medication Class, Rx Days
Beers Criteria Medication Class, Binary Indicator
Beers Criteria Medication Class, # Rx
Charlson Comorbidity Score Indicator
Elixhauser Comorbidity Indicator
Frailty Measure Indicator
Elixhauser Comorbidity Indicator
Frailty Measure Indicator
Beers Criteria Medication Class, Rx Days
Beers Criteria Medication Class, Binary Indicator
Beers Criteria Medication Class, # Rx
Hospital Admissions, Binary Indicator
Elixhauser Comorbidity Indicator
Elixhauser Comorbidity Indicator
(continued)
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Col#
97
179
96
107
125
2
27
6
157
81
180
80
191
85
181
84
87
182
86
83
183
82
79
184
78
154
190
29
37
103
26
110
99
185
98
111
136
108
9
17

Variable
Laxative_Dys
Laxative_IND
Laxative_Rx
lipid
Male
MEMDAYS
MS
MSA
Narcotic
Narcotic_Dys
Narcotic_IND
Narcotic_Rx
NoBeersRx_IND
Nonbarbiturate_sedative_hypn_Dys
Nonbarbiturate_sedative_hypn_IND
Nonbarbiturate_sedative_hypn_Rx
Nonbenzodiazepine_sedative_Dys
Nonbenzodiazepine_sedative_IND
Nonbenzodiazepine_sedative_Rx
NonCOX_NSAIDs_Dys
NonCOX_NSAIDs_IND
NonCOX_NSAIDs_Rx
NSAIDs_Dys
NSAIDs_IND
NSAIDs_Rx
OtherBeers
OtherRx_IND
Otitis
Paral
paraplegic
Parkin
pd
Phenothiazines_Dys
Phenothiazines_IND
Phenothiazines_Rx
podiatry
pscore
psychiatric
PulmHeart
RA

Label
Beers Criteria Medication Class, Rx Days
Beers Criteria Medication Class, Binary Indicator
Beers Criteria Medication Class, # Rx
Charlson Comorbidity Score Indicator
Gender, Male
Member Days
Elixhauser Comorbidity Indicator
Metropolitan Statistical Area
Narcotic, Binary Indicator
Beers Criteria Medication Class, Rx Days
Beers Criteria Medication Class, Binary Indicator
Beers Criteria Medication Class, # Rx
No Beers Medications Taken, Binary Indicator
Beers Criteria Medication Class, Rx Days
Beers Criteria Medication Class, Binary Indicator
Beers Criteria Medication Class, # Rx
Beers Criteria Medication Class, Rx Days
Beers Criteria Medication Class, Binary Indicator
Beers Criteria Medication Class, # Rx
Beers Criteria Medication Class, Rx Days
Beers Criteria Medication Class, Binary Indicator
Beers Criteria Medication Class, # Rx
Beers Criteria Medication Class, Rx Days
Beers Criteria Medication Class, Binary Indicator
Beers Criteria Medication Class, # Rx
Other Beers Medication Class, Categorical, Study Specific
Other Beers Medication Class, Binary Indicator, Study
Specific
Elixhauser Comorbidity Indicator
Elixhauser Comorbidity Indicator
Charlson Comorbidity Score Indicator
Elixhauser Comorbidity Indicator
Charlson Comorbidity Score Indicator
Beers Criteria Medication Class, Rx Days
Beers Criteria Medication Class, Binary Indicator
Beers Criteria Medication Class, # Rx
Frailty Measure Indicator
Estimated Probability
Charlson Comorbidity Score Indicator
Elixhauser Comorbidity Indicator
Elixhauser Comorbidity Indicator
(continued)
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Col#
7
127
128
129
130
131
112
25
24
115
4
23
89
186
88
114
34
145
36
91
187
90
142
141
140
93
188
92
31
95
189
94
30
117
135
137
139
138

Variable
REGION
Region_1
Region_2
Region_3
Region_4
Region_5
rehab
Scizo
Senile
sepsis
SEX
Sicle
Skeletal_muscle_relaxants_Dys
Skeletal_muscle_relaxants_IND
Skeletal_muscle_relaxants_Rx
skinulcer
SLE
Studycost
SUlcer
Sulfonylureas_Dys
Sulfonylureas_IND
Sulfonylureas_Rx
SumIP13
SumOP13
SumRx13
Tertiary_TCAs_Dys
Tertiary_TCAs_IND
Tertiary_TCAs_Rx
Valve
Vasodilator_Dys
Vasodilator_IND
Vasodilator_Rx
Vertigo
weakness
_LEVEL_
_Lps
_MatchID
_MATCHWGT_

Label
Region, Categorical
Region, Northeast, Binary Indicator
Region, North Central, Binary Indicator
Region, South, Binary Indicator
Region, West, Binary Indicator
Region, Unknown, Binary Indicator
Frailty Measure Indicator
Elixhauser Comorbidity Indicator
Elixhauser Comorbidity Indicator
Charlson Comorbidity Score Indicator
Gender of Patient
Elixhauser Comorbidity Indicator
Beers Criteria Medication Class, Rx Days
Beers Criteria Medication Class, Binary Indicator
Beers Criteria Medication Class, # Rx
Charlson Comorbidity Score Indicator
Elixhauser Comorbidity Indicator
Total Cost, Inpatient+Outpatient+Rx
Elixhauser Comorbidity Indicator
Beers Criteria Medication Class, Rx Days
Beers Criteria Medication Class, Binary Indicator
Beers Criteria Medication Class, # Rx
Total Cost, Inpatient
Total Cost, Outpatient
Total Cost, Rx
Beers Criteria Medication Class, Rx Days
Beers Criteria Medication Class, Binary Indicator
Beers Criteria Medication Class, # Rx
Elixhauser Comorbidity Indicator
Beers Criteria Medication Class, Rx Days
Beers Criteria Medication Class, Binary Indicator
Beers Criteria Medication Class, # Rx
Elixhauser Comorbidity Indicator
Frailty Measure Indicator
Response Value
Logit of Propensity Score
Matched ID number
Matched obs ATT weight
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Table 18
List of dataset variables from O'Neill Roldan (2018)
Col#
144
147
3
39
38
41
40
120
43
42
45
44
47
46
49
48
51
50
53
52
55
54
57
56
59
58
61
60
63
62
148
100
113
14
65
64
158
67

Variable
ADMS
adms_0
AGE
Alpha_Agonist_Central_Dys
Alpha_Agonist_Central_Rx
Alpha_Blocker_Dys
Alpha_Blocker_Rx
Ambu
Antiarrhythmic_Dys
Antiarrhythmic_Rx
Antiemetics_Dys
Antiemetics_Rx
Antihistamine_1st_Gen_Dys
Antihistamine_1st_Gen_Rx
Antihypertensive_Dys
Antihypertensive_Rx
Antiinfective_Dys
Antiinfective_Rx
Antiparkinson_agent_Dys
Antiparkinson_agent_Rx
Antipsychotics_FirstGen_Dys
Antipsychotics_FirstGen_Rx
Antipsychotics_SecondGen_Dys
Antipsychotics_SecondGen_Rx
Antispasmodic_Dys
Antispasmodic_Rx
Antithrombotic_Dys
Antithrombotic_Rx
Anxiolytic_Dys
Anxiolytic_Rx
AnyADM
AnyBeers
arthritis
Asthma
Barbiturates_Dys
Barbiturates_Rx
BeersCat
Benzodiazepines_Long_Acting_Dys

Label
# of Hospital Admissions
# of Hospital Admissions
Age of Patient
Beers Criteria Medication Class, Rx Days
Beers Criteria Medication Class, # Rx
Beers Criteria Medication Class, Rx Days
Beers Criteria Medication Class, # Rx
Frailty Measure Indicator
Beers Criteria Medication Class, Rx Days
Beers Criteria Medication Class, # Rx
Beers Criteria Medication Class, Rx Days
Beers Criteria Medication Class, # Rx
Beers Criteria Medication Class, Rx Days
Beers Criteria Medication Class, # Rx
Beers Criteria Medication Class, Rx Days
Beers Criteria Medication Class, # Rx
Beers Criteria Medication Class, Rx Days
Beers Criteria Medication Class, # Rx
Beers Criteria Medication Class, Rx Days
Beers Criteria Medication Class, # Rx
Beers Criteria Medication Class, Rx Days
Beers Criteria Medication Class, # Rx
Beers Criteria Medication Class, Rx Days
Beers Criteria Medication Class, # Rx
Beers Criteria Medication Class, Rx Days
Beers Criteria Medication Class, # Rx
Beers Criteria Medication Class, Rx Days
Beers Criteria Medication Class, # Rx
Beers Criteria Medication Class, Rx Days
Beers Criteria Medication Class, # Rx
Any Hospital Admission, Binary Indicator
Any Beers Medication Present, Binary Indicator
Frailty Measure Indicator
Elixhauser Comorbidity Indicator
Beers Criteria Medication Class, Rx Days
Beers Criteria Medication Class, # Rx
Beers Criteria Medication Class, Categorical, Study-based
Beers Criteria Medication Class, Rx Days
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Col#
66
69
68
101
116
105
32
22
8
12
102
10
11
13
16
143
146
104
18
19
118
109
71
70
15
5
1
28
73
72
126
123
134
132
133
122
75
74
106
21

Variable
Benzodiazepines_Long_Acting_Rx
Benzodiazepines_Short_Acting_Dys
Benzodiazepines_Short_Acting_Rx
bladder
braininj
cancer
Carditis
CF
CharlsScore
CHF
coagulopathy
ConductHeart
ConductHeartB
COPD
CRF
Days
days_0
dementia
Diab
DiabComp
diabetes
diffwalk
Diuretic_Dys
Diuretic_Rx
Divert
EGEOLOC
ENROLID
Epil
Ergoloid_Dys
Ergoloid_Rx
Female
FrailCat
FrailCat_0
FrailCat_1
FrailCat_2
FrailScore
Gut_motility_stimulator_Dys
Gut_motility_stimulator_Rx
heartfail
Hep

Label
Beers Criteria Medication Class, # Rx
Beers Criteria Medication Class, Rx Days
Beers Criteria Medication Class, # Rx
Charlson Comorbidity Score Indicator
Charlson Comorbidity Score Indicator
Charlson Comorbidity Score Indicator
Elixhauser Comorbidity Indicator
Elixhauser Comorbidity Indicator
Charlson Score
Elixhauser Comorbidity Indicator
Charlson Comorbidity Score Indicator
Elixhauser Comorbidity Indicator
Elixhauser Comorbidity Indicator
Elixhauser Comorbidity Indicator
Elixhauser Comorbidity Indicator
Length of Stay, # of Days
Length of Stay, # of Days
Charlson Comorbidity Score Indicator
Elixhauser Comorbidity Indicator
Elixhauser Comorbidity Indicator
Charlson Comorbidity Score Indicator
Frailty Measure Indicator
Beers Criteria Medication Class, Rx Days
Beers Criteria Medication Class, # Rx
Elixhauser Comorbidity Indicator
Geographic Location Employee
Enrollee ID
Elixhauser Comorbidity Indicator
Beers Criteria Medication Class, Rx Days
Beers Criteria Medication Class, # Rx
Gender, Female
Frailty Category, Categorical
Frailty Indicator, Pre-Frail, Binary Indicator
Frailty Indicator, Frail, Binary Indicator
Frailty Indicator, Robust, Binary Indicator
Calculated Frailty Score
Beers Criteria Medication Class, Rx Days
Beers Criteria Medication Class, # Rx
Charlson Comorbidity Score Indicator
Elixhauser Comorbidity Indicator
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Col#
119
20
121
77
76
124
33
35
97
96
107
125
2
27
6
157
81
80
85
84
87
86
83
82
79
78
154
29
37
103
26
110
99
98
111
136
108
9
17
7

Variable
HHBed
HIV
HomeO2
Hormones_Dys
Hormones_Rx
HospitalAdm
Hyp
LateStroke
Laxative_Dys
Laxative_Rx
lipid
Male
MEMDAYS
MS
MSA
Narcotic
Narcotic_Dys
Narcotic_Rx
Nonbarbiturate_sedative_hypn_Dys
Nonbarbiturate_sedative_hypn_Rx
Nonbenzodiazepine_sedative_Dys
Nonbenzodiazepine_sedative_Rx
NonCOX_NSAIDs_Dys
NonCOX_NSAIDs_Rx
NSAIDs_Dys
NSAIDs_Rx
OtherBeers
Otitis
Paral
paraplegic
Parkin
pd
Phenothiazines_Dys
Phenothiazines_Rx
podiatry
pscore
psychiatric
PulmHeart
RA
REGION

Label
Frailty Measure Indicator
Elixhauser Comorbidity Indicator
Frailty Measure Indicator
Beers Criteria Medication Class, Rx Days
Beers Criteria Medication Class, # Rx
Hospital Admissions, Binary Indicator
Elixhauser Comorbidity Indicator
Elixhauser Comorbidity Indicator
Beers Criteria Medication Class, Rx Days
Beers Criteria Medication Class, # Rx
Charlson Comorbidity Score Indicator
Gender, Male
Member Days
Elixhauser Comorbidity Indicator
Metropolitan Statistical Area
Narcotic, Binary Indicator
Beers Criteria Medication Class, Rx Days
Beers Criteria Medication Class, # Rx
Beers Criteria Medication Class, Rx Days
Beers Criteria Medication Class, # Rx
Beers Criteria Medication Class, Rx Days
Beers Criteria Medication Class, # Rx
Beers Criteria Medication Class, Rx Days
Beers Criteria Medication Class, # Rx
Beers Criteria Medication Class, Rx Days
Beers Criteria Medication Class, # Rx
Other Beers Medication Class, Categorical, Study Specific
Elixhauser Comorbidity Indicator
Elixhauser Comorbidity Indicator
Charlson Comorbidity Score Indicator
Elixhauser Comorbidity Indicator
Charlson Comorbidity Score Indicator
Beers Criteria Medication Class, Rx Days
Beers Criteria Medication Class, # Rx
Frailty Measure Indicator
Estimated Probability
Charlson Comorbidity Score Indicator
Elixhauser Comorbidity Indicator
Elixhauser Comorbidity Indicator
Region, Categorical
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Col#
127
128
129
130
131
112
25
24
115
4
23
89
88
114
34
145
36
91
90
142
141
140
93
92
31
95
94
30
117
135
137
139
138

Variable
Region_1
Region_2
Region_3
Region_4
Region_5
rehab
Scizo
Senile
sepsis
SEX
Sicle
Skeletal_muscle_relaxants_Dys
Skeletal_muscle_relaxants_Rx
skinulcer
SLE
Studycost
SUlcer
Sulfonylureas_Dys
Sulfonylureas_Rx
SumIP13
SumOP13
SumRx13
Tertiary_TCAs_Dys
Tertiary_TCAs_Rx
Valve
Vasodilator_Dys
Vasodilator_Rx
Vertigo
weakness
_LEVEL_
_Lps
_MatchID
_MATCHWGT_

Label
Region, Northeast, Binary Indicator
Region, North Central, Binary Indicator
Region, South, Binary Indicator
Region, West, Binary Indicator
Region, Unknown, Binary Indicator
Frailty Measure Indicator
Elixhauser Comorbidity Indicator
Elixhauser Comorbidity Indicator
Charlson Comorbidity Score Indicator
Gender of Patient
Elixhauser Comorbidity Indicator
Beers Criteria Medication Class, Rx Days
Beers Criteria Medication Class, # Rx
Charlson Comorbidity Score Indicator
Elixhauser Comorbidity Indicator
Total Cost, Inpatient+Outpatient+Rx
Elixhauser Comorbidity Indicator
Beers Criteria Medication Class, Rx Days
Beers Criteria Medication Class, # Rx
Total Cost, Inpatient
Total Cost, Outpatient
Total Cost, Rx
Beers Criteria Medication Class, Rx Days
Beers Criteria Medication Class, # Rx
Elixhauser Comorbidity Indicator
Beers Criteria Medication Class, Rx Days
Beers Criteria Medication Class, # Rx
Elixhauser Comorbidity Indicator
Frailty Measure Indicator
Response Value
Logit of Propensity Score
Matched ID number
Matched obs ATT weight
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Table 19
List of ICD-9 codes for Charlson Score Index indicator variables
Charlson Comorbidity Condition
AIDS/HIV
Any malignancy, except malignant
neoplasm of skin
Cerebrovascular disease
Chronic pulmonary disease
Congestive heart failure
Dementia
Diabetes with chronic complication
Diabetes without chronic complication
Hemiplegia or paraplegia
Metastatic solid tumour
Mild liver disease
Moderate or severe liver disease
Myocardial infarction
Peptic ulcer disease
Peripheral vascular disease

Renal disease
Rheumatic disease
Source: (Quan et al., 2005)

ICD-9 Code Range/Values
042.x - 044.x
140.x - 172.x, 174.x - 195.8, 200.x - 208.x, 238.6
362.34, 430.x - 438.x
416.8, 416.9, 490.x - 505.x, 506.4, 508.1, 508.8
398.91, 402.01, 402.11, 402.91, 404.01, 404.03, 404.11, 404.13,
404.91, 404.93, 425.4 - 425.9, 428.x
290.x, 294.1, 331.2
250.4 - 250.7
250.0 - 250.3, 250.8, 250.9
334.1, 342.x, 343.x, 344.0 - 344.6, 344.9
196.x - 199.x
070.22, 070.23, 070.32, 070.33, 070.44, 070.54, 070.6, 070.9, 570.x,
571.x, 573.3, 573.4, 573.8, 573.9, V42.7
456.0 - 456.2, 572.2- 572.8
410.x, 412.x
531.x - 534.x
093.0, 437.3, 440.x, 441.x, 443.1 - 443.9, 447.1, 557.1, 557.9, V43.4
403.01, 403.11, 403.91, 404.02, 404.03, 404.12, 404.13, 404.92,
404.93, 582.x, 583.0 - 583.7, 585.x, 586.x, 588.0, V42.0, V45.1,
V56.x
446.5, 710.0 - 710.4, 714.0 - 714.2, 714.8, 725.x
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Table 20
List of ICD-9 codes for Elixhauser Comorbidity Index indicator variables
Elixhauser Condition
AIDS/HIV
Alcohol abuse
Blood loss anemia
Cardiac arrhythmias
Chronic pulmonary disease
Coagulopathy
Congestive heart failure
Deficiency anemia
Depression
Diabetes, complicated
Diabetes, uncomplicated
Drug abuse
Fluid and electrolyte disorders
Hypertension, complicated
Hypertension, uncomplicated
Hypothyroidism

Liver disease
Lymphoma
Metastatic cancer
Obesity
Other neurological disorders
Paralysis
Peptic ulcer disease, excluding bleeding
Peripheral vascular disorders
Psychoses
Pulmonary circulation disorders
Renal failure
Rheumatoid arthritis
Solid tumor without metastasis
Valvular disease
Weight loss
Source: (Quan et al., 2005)

ICD-9 Code Range/Values
042.x - 044.x
265.2, 291.1 - 291.3, 291.5 - 291.9, 303.0, 303.9, 305.0, 357.5,
425.5, 535.3, 571.0 - 571.3, 980.x, V11.3
280.0
426.0, 426.13, 426.7, 426.9, 426.10, 426.12, 427.0 - 427.4, 427.6 427.9, 785.0, 996.01, 996.04, V45.0, V53.3
416.8, 416.9, 490.x - 505.x, 506.4, 508.1, 508.8
286.x, 287.1, 287.3 - 287.5
398.91, 402.01, 402.11, 402.91, 404.01, 404.03, 404.11, 404.13,
404.91, 404.93, 425.4 - 425.9, 428.x
280.1 - 280.9, 281.x
296.2, 296.3, 296.5, 300.4, 309.x, 311
250.4 - 250.9
250.0 - 250.3
292.x, 304.x, 305.2 - 305.9, V65.42
253.6, 276.x
402.x - 405.x
401.x
240.9, 243.x, 244.x, 246.1, 246.8
070.22, 070.23, 070.32, 070.33, 070.44, 070.54, 070.6, 070.9, 456.0
- 456.2, 570.x, 571.x, 572.2 - 572.8, 573.3, 573.4, 573.8, 573.9,
V42.7
200.x - 202.x, 203.0, 238.6
196.x - 199.x
278.0
331.9, 332.0, 332.1, 333.4, 333.5, 333.92, 334.x - 335.x, 336.2,
340.x, 341.x, 345.x, 348.1, 348.3, 780.3, 784.3
334.1, 342.x, 343.x, 344.0 - 344.6, 344.9
531.7, 531.9, 532.7, 532.9, 533.7, 533.9, 534.7, 534.9
093.0, 437.3, 440.x, 441.x, 443.1 - 443.9, 447.1, 557.1, 557.9, V43.4
293.8, 295.x, 296.04, 296.14, 296.44, 296.54, 297.x, 298.x
415.0, 415.1, 416.x, 417.0, 417.8, 417.9
403.01, 403.11, 403.91, 404.02, 404.03, 404.12, 404.13, 404.92,
404.93, 585.x, 586.x, 588.0, V42.0, V45.1, V56.x
446.x, 701.0, 710.0 - 710.4, 710.8, 710.9, 711.2, 714.x, 719.3, 720.x,
725.x, 728.5, 728.89, 729.30
140.x - 172.x, 174.x - 195.x
093.2, 394.x - 397.x, 424.x, 746.3 - 746.6, V42.2, V43.3
260.x - 263.x, 783.2, 799.4

